Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome caused by germline pathogenic variants in the TP53 tumor suppressor gene. It is characterized by a dramatically increased lifetime risk of multiple cancers, including soft tissue sarcomas, osteosarcomas, premenopausal breast cancer (often HER2-positive), brain tumors (including choroid plexus carcinoma), pediatric adrenocortical carcinoma, and leukemias. LFS exemplifies the two-hit hypothesis: patients inherit one mutant TP53 allele and somatic loss of the remaining wild-type allele (loss-of-heterozygosity) initiates tumorigenesis. Beyond classical loss-of-function, hotspot missense mutants (e.g., R175H, R248W, R273H) exert dominant-negative and gain-of-function effects that drive earlier onset, chemoresistance, and metastasis. The syndrome demonstrates remarkable phenotypic variability, with cumulative cancer risk approaching 100% by age 70; 43% of affected carriers develop multiple primary malignancies. Tissue tropism is shaped by tissue-specific p53 functions including bioenergetic regulation (mitochondrial OXPHOS), control of stem/progenitor differentiation (mesenchymal, hematopoietic, neuroepithelial), and metabolic surveillance (cystine uptake and ferroptosis).
Ask a research question about Li-Fraumeni Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Li-Fraumeni Syndrome
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-04-25T00:00:00Z'
description: >-
Li-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition syndrome
caused by germline pathogenic variants in the TP53 tumor suppressor gene. It is
characterized by a dramatically increased lifetime risk of multiple cancers, including
soft tissue sarcomas, osteosarcomas, premenopausal breast cancer (often HER2-positive),
brain tumors (including choroid plexus carcinoma), pediatric adrenocortical carcinoma,
and leukemias. LFS exemplifies the two-hit hypothesis: patients inherit one mutant
TP53 allele and somatic loss of the remaining wild-type allele (loss-of-heterozygosity)
initiates tumorigenesis. Beyond classical loss-of-function, hotspot missense mutants
(e.g., R175H, R248W, R273H) exert dominant-negative and gain-of-function effects
that drive earlier onset, chemoresistance, and metastasis. The syndrome demonstrates
remarkable phenotypic variability, with cumulative cancer risk approaching 100%
by age 70; 43% of affected carriers develop multiple primary malignancies. Tissue
tropism is shaped by tissue-specific p53 functions including bioenergetic regulation
(mitochondrial OXPHOS), control of stem/progenitor differentiation (mesenchymal,
hematopoietic, neuroepithelial), and metabolic surveillance (cystine uptake and
ferroptosis).
categories:
- Hereditary Cancer Syndrome
- Cancer Predisposition Syndrome
parents:
- hereditary cancer-predisposing syndrome
has_subtypes:
- name: Classic Li-Fraumeni Syndrome
description: >-
Defined by classic clinical criteria: proband with sarcoma before age 45,
first-degree relative with cancer before 45, and another first- or second-degree
relative with cancer before 45 or sarcoma at any age.
- name: Li-Fraumeni-Like Syndrome
description: >-
Families meeting relaxed criteria (Birch or Eeles) who have germline TP53
mutations but do not fulfill classic LFS criteria. May have later onset
or fewer affected family members.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_tp53_loss_genome_instability_multitumor_model
hypothesis_label: Canonical TP53 Loss-of-Function / Genome Instability / Multi-Tumor Predisposition Model
status: CANONICAL
description: >-
Li-Fraumeni syndrome (LFS) is caused by germline heterozygous loss-of-function variants in TP53 on
17p13.1 encoding the p53 tumor suppressor. p53 is the central node of the genome guardian network,
integrating signals of DNA damage, oncogenic stress, hypoxia, and ribosomal/nucleolar dysfunction to
execute G1/G2 cell-cycle arrest, apoptosis, senescence, ferroptosis, and metabolic reprogramming via
transcription of CDKN1A, BAX, PUMA, MDM2, and many other targets. Somatic biallelic TP53
inactivation accelerates accumulation of genomic instability, chromosomal aneuploidy, and oncogene
activation, producing the LFS-defining early-onset cancer spectrum: sarcomas, breast cancers (young
women), brain tumors, adrenocortical carcinoma, leukemia, and lung cancer. Mouse Trp53^+/- models
recapitulate the cancer-prone phenotype, and clinical surveillance with whole-body MRI (Toronto
protocol) reduces cancer-specific mortality, corroborating the TP53-loss / genome-instability axis
as the canonical model.
notes: >-
Retained as CANONICAL. The 2026 openscientist
hypothesis-search report
(kb/hypotheses/Li-Fraumeni_Syndrome/canonical_tp53_loss_genome_instability_multitumor_model)
confirms TP53 loss-of-function → loss of genome-guardian
activity → accelerated chromosomal instability and oncogene
activation → broad pediatric/adult tumor predisposition
spectrum (sarcomas, breast cancers, brain tumors,
adrenocortical carcinoma, leukemia, lung cancer). Validated
by mouse Trp53^+/- recapitulating the cancer-prone phenotype,
>75% lifetime cancer risk in carriers, and the Toronto Protocol
whole-body MRI surveillance significantly reducing cancer-
specific mortality. Three refinements: (1) the second TP53
hit is not always required — heterozygous loss with dominant-
negative or gain-of-function effects (R175H, R248Q hotspots)
drives tumorigenesis through perturbation of cellular
senescence, metabolic reprogramming, and stem-cell
homeostasis; (2) phenotypic heterogeneity reflects modifier
loci, MDM2 SNP309, and environmental DNA-damage exposure;
(3) the canonical model emphasizes genome instability but
p53 also coordinates ferroptosis, autophagy, and metabolic
pathways now recognized as integral to tumor suppression.
Investigational therapies targeting mutant p53 reactivation
(eprenetapopt/APR-246, PC14586) and selective synthetic
lethality (WEE1, ATR inhibitors) are validating the genome-
instability axis pharmacologically.
evidence:
- reference: PMID:25743702
reference_title: "Genomic landscape of paediatric adrenocortical tumours."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "TP53 mutations and chromosome 17 LOH with selection against wild-type TP53 are observed in 28 ACTs (76%)"
explanation: >
Existing canonical mechanism citation in the dismech
knowledge base, used as the seed for the hypothesis-search
deep-research run.
pathophysiology:
- name: Germline TP53 Heterozygosity
description: >-
Carriers inherit one pathogenic TP53 allele and one wild-type allele in
every nucleated cell ("first hit"). Most pathogenic alleles are missense
substitutions in the DNA-binding domain (exons 5-8); approximately 70-85%
of LFS families carrying classic criteria harbor an identifiable germline
TP53 variant. Heterozygosity alone produces partial p53 haploinsufficiency
and primes carriers for somatic transformation, but typically requires a
second somatic hit for overt tumorigenesis.
genes:
- preferred_term: TP53
term:
id: hgnc:11998
label: TP53
downstream:
- target: Loss of Heterozygosity (Second Hit)
description: >-
Most LFS tumors lose the wild-type TP53 allele somatically, completing
biallelic inactivation per the Knudson two-hit model.
- target: Mutant p53 Stabilization and Gain-of-Function
description: >-
In tumors carrying hotspot missense alleles, residual mutant p53 protein
is markedly stabilized and exerts dominant-negative and oncogenic
gain-of-function activities even before complete LOH.
- name: Loss of Heterozygosity (Second Hit)
description: >-
Somatic loss of the remaining wild-type TP53 allele on chromosome 17p13.1
("second hit") completes biallelic p53 inactivation and is observed in the
vast majority of LFS-associated tumors. In pediatric adrenocortical
carcinoma the second hit is typically copy-neutral LOH of chromosome 17
with selection against the wild-type allele, frequently combined with
chromosome 11p LOH and IGF2 over-expression. LOH is also a prerequisite
for stabilization and gain-of-function activity of mutant p53 in vivo.
evidence:
- reference: PMID:25743702
reference_title: "Genomic landscape of paediatric adrenocortical tumours."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
TP53 mutations and chromosome 17 LOH with selection against wild-type TP53
are observed in 28 ACTs (76%)
explanation: >-
Whole-genome/whole-exome analysis of 37 pediatric adrenocortical tumours
demonstrates that somatic LOH of chromosome 17 with selection against the
wild-type TP53 allele is the dominant second-hit mechanism in this LFS
tumor type, validating two-hit tumorigenesis at the genomic level.
downstream:
- target: TP53 Tumor Suppressor Loss
description: Biallelic TP53 inactivation removes wild-type p53 tumor suppressor activity.
- target: Mutant p53 Stabilization and Gain-of-Function
description: >-
In tumors carrying missense alleles, LOH allows the mutant protein to
accumulate to high levels and acquire neomorphic GOF activities.
- name: Mutant p53 Stabilization and Gain-of-Function
description: >-
Hotspot missense alleles (R175H, R248W, R248Q, R273H, R273C, G245S) escape
MDM2-mediated turnover and accumulate in tumor cells, particularly after
LOH. Stabilized mutant p53 exerts two non-canonical activities: (1)
dominant-negative inhibition of any residual wild-type p53 by hetero-oligo-
merization, and (2) gain-of-function activities mediated by aberrant
interaction with transcription factors (NF-kB, HIF-1alpha, SREBP1, p63,
p73, EZH2) and cytoplasmic effectors. GOF mutant p53 drives metabolic
reprogramming, cancer stem-cell expansion, EMT, immune evasion (PD-L1
upregulation, MHC-I downregulation), chemoresistance, and metastasis.
Carriers of dominant-negative missense alleles develop their first tumor
at younger ages than carriers of null alleles or genomic rearrangements.
evidence:
- reference: PMID:26014290
reference_title: "Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The mean age of tumor onset was statistically different (P < .05) between
carriers harboring dominant-negative missense mutations (21.3 years) and
those with all types of loss of function mutations (28.5 years) or genomic
rearrangements (35.8 years).
explanation: >-
The 415-carrier French LFS cohort demonstrates a clinically meaningful
gradient of tumor onset by mutation class, supporting the dominant-negative
and gain-of-function paradigm where missense alleles are biologically more
severe than simple loss-of-function alleles.
- reference: PMID:33644030
reference_title: "Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Frequent p53 mutations (mutp53) not only abolish tumor suppressor
capacities but confer various gain-of-function (GOF) activities that
impacts molecules and pathways now regarded as central for tumor
development and progression.
explanation: >-
Mechanistic review summarizing how mutant p53 GOF promotes Warburg
metabolism, mevalonate pathway activation, cancer stem-cell phenotypes,
and immune evasion - mechanisms relevant to LFS tumor aggressiveness.
downstream:
- target: Increased Mitochondrial Oxidative Phosphorylation
description: >-
Mutant p53 GOF and loss of wild-type p53 reshape bioenergetic homeostasis
in LFS, with a paradoxical increase in mitochondrial respiration in
multiple tissues.
- target: Tumor Development
description: >-
Mutant p53 GOF cooperates with biallelic TP53 inactivation to drive
aggressive transformation, EMT, chemoresistance, and metastasis.
- name: TP53 Tumor Suppressor Loss
description: >-
Once both TP53 alleles are inactivated, p53 transcriptional and
non-transcriptional tumor-suppressor activities are abolished, removing a
central checkpoint against malignant transformation. Beyond classic cell-
cycle/apoptosis programs, this includes loss of metabolic surveillance
(ferroptosis induction, oxidative phosphorylation regulation), senescence,
autophagy modulation, and stem-cell differentiation control.
biological_processes:
- preferred_term: signal transduction by p53 class mediator
modifier: DECREASED
term:
id: GO:0072331
label: signal transduction by p53 class mediator
downstream:
- target: Loss of DNA Damage Response
description: p53 loss impairs cellular response to genotoxic stress
- target: Loss of Cell Cycle Checkpoint Control
description: p53 loss allows cells with DNA damage to continue cycling
- target: Impaired Apoptosis
description: p53 loss prevents elimination of damaged cells
- target: Loss of Ferroptosis Surveillance
description: >-
p53 normally represses SLC7A11 to restrict cystine uptake and sensitize
cells to ferroptosis; this non-canonical tumor-suppressor function is
lost in TP53-null cells.
- target: Senescence Escape
description: >-
Loss of p53-induced cellular senescence permits indefinite proliferation
of damaged cells.
- target: Aberrant Mesenchymal Stem Cell Differentiation
description: >-
p53 loss disrupts H19/IMP/DCN-mediated osteogenic differentiation in
mesenchymal progenitors, biasing toward sarcomagenesis.
- target: Hematopoietic Clonal Expansion
description: >-
p53-mutant hematopoietic stem/progenitor cells display enhanced self-
renewal and clonal advantage, particularly under chemotherapy or radiation
stress.
- name: Loss of Ferroptosis Surveillance
description: >-
Wild-type p53 transcriptionally represses SLC7A11, limiting cystine uptake
via the xCT antiporter and sensitizing cells to ferroptosis - an iron-
dependent, lipid-peroxidation-driven form of regulated cell death. Loss of
p53 (or expression of certain mutant alleles that fail to repress SLC7A11)
derepresses SLC7A11, increases intracellular GSH, blunts lipid peroxidation,
and renders cells refractory to ROS-induced ferroptosis. This non-canonical
tumor-suppressor activity is independent of cell-cycle arrest, apoptosis,
and senescence and contributes to LFS tumor susceptibility and to the
radiosensitivity of p53-wild-type tumors.
biological_processes:
- preferred_term: ferroptosis
modifier: DECREASED
term:
id: GO:0097707
label: ferroptosis
evidence:
- reference: PMID:25799988
reference_title: "Ferroptosis as a p53-mediated activity during tumour suppression."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
p53 inhibits cystine uptake and sensitizes cells to ferroptosis, a
non-apoptotic form of cell death, by repressing expression of SLC7A11
explanation: >-
Seminal Nature paper establishing p53-mediated ferroptosis as a non-canonical
tumor suppressor mechanism, lost in TP53-deficient cells and therefore in
LFS tumors.
downstream:
- target: Tumor Development
description: >-
Failure of ferroptosis allows oxidatively stressed cells to escape death
and contribute to tumor formation.
- name: Senescence Escape
description: >-
p53 induces stable cell-cycle exit (cellular senescence) in response to
oncogenic stress, telomere attrition, and DNA damage via p21 (CDKN1A) and
SASP-related programs. Loss of p53 disables this barrier, allowing pre-
malignant cells to bypass senescence and continue proliferating despite
accumulated damage.
biological_processes:
- preferred_term: cellular senescence
modifier: DECREASED
term:
id: GO:0090398
label: cellular senescence
downstream:
- target: Tumor Development
description: Bypass of senescence permits indefinite proliferation of damaged cells.
- name: Increased Mitochondrial Oxidative Phosphorylation
description: >-
LFS carriers display constitutively elevated mitochondrial respiration in
skeletal muscle and other tissues, reflecting loss of p53-mediated
repression of mitochondrial biogenesis (TFAM, SCO2). Increased OXPHOS
raises baseline ROS production and biosynthetic precursor availability,
creating a permissive metabolic environment for transformation. Genetic
or pharmacologic disruption of mitochondrial respiration (e.g., metformin)
extends cancer-free survival in mouse models, supporting a causal role in
LFS tumorigenesis.
biological_processes:
- preferred_term: oxidative phosphorylation
modifier: INCREASED
term:
id: GO:0006119
label: oxidative phosphorylation
evidence:
- reference: PMID:23484829
reference_title: "Increased oxidative metabolism in the Li-Fraumeni syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
family members with these mutations have increased oxidative phosphorylation
of skeletal muscle
explanation: >-
In vivo 31P-MRS measurement in TP53 carriers from LFS families demonstrates
increased skeletal-muscle oxidative phosphorylation, providing direct human
evidence that p53 governs bioenergetic homeostasis and that this is altered
in LFS.
- reference: PMID:27869650
reference_title: "Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
genetic or pharmacologic disruption of mitochondrial respiration improves
cancer-free survival
explanation: >-
Mouse model evidence and human pilot study demonstrating that targeting
the LFS-associated metabolic shift with metformin delays tumorigenesis,
supporting OXPHOS as a causal driver in LFS.
downstream:
- target: Tumor Development
description: >-
Elevated mitochondrial respiration provides metabolic precursors and ROS
that cooperate with genomic instability to promote transformation.
- name: Loss of DNA Damage Response
description: >-
p53 is a master regulator of the DNA damage response. Upon detecting DNA
damage, p53 activates transcription of genes involved in cell cycle arrest,
DNA repair, and apoptosis. Loss of p53 function eliminates this critical
surveillance mechanism.
biological_processes:
- preferred_term: DNA damage response, signal transduction by p53 class mediator
modifier: DECREASED
term:
id: GO:0030330
label: DNA damage response, signal transduction by p53 class mediator
downstream:
- target: Genomic Instability
description: Unchecked DNA damage leads to mutation accumulation
- name: Loss of Cell Cycle Checkpoint Control
description: >-
p53 induces G1 arrest in response to DNA damage by activating p21 (CDKN1A)
transcription, which inhibits cyclin-dependent kinases. Without p53, cells
with damaged DNA continue through the cell cycle, replicating mutations.
biological_processes:
- preferred_term: G1/S transition of mitotic cell cycle
modifier: ABNORMAL
term:
id: GO:0000082
label: G1/S transition of mitotic cell cycle
downstream:
- target: Genomic Instability
description: Damaged cells replicate, accumulating mutations
- name: Impaired Apoptosis
description: >-
p53 promotes apoptosis through transcriptional activation of pro-apoptotic
genes (BAX, PUMA, NOXA) and repression of anti-apoptotic BCL2. Loss of p53
allows damaged and potentially transformed cells to survive and proliferate.
biological_processes:
- preferred_term: intrinsic apoptotic signaling pathway by p53 class mediator
modifier: DECREASED
term:
id: GO:0072332
label: intrinsic apoptotic signaling pathway by p53 class mediator
- preferred_term: apoptotic process
modifier: DECREASED
term:
id: GO:0006915
label: apoptotic process
downstream:
- target: Tumor Development
description: Damaged cells escape elimination and undergo malignant transformation
- name: Genomic Instability
description: >-
Loss of p53-mediated checkpoints and DNA repair coordination leads to
progressive accumulation of genomic alterations including point mutations,
chromosomal rearrangements, and aneuploidy. This genomic instability
accelerates tumor development and drives cancer heterogeneity.
biological_processes:
- preferred_term: DNA repair
modifier: DECREASED
term:
id: GO:0006281
label: DNA repair
downstream:
- target: Tumor Development
description: Accumulated mutations drive malignant transformation
- name: Tumor Development
description: >-
The combination of impaired DNA damage response, loss of cell cycle checkpoints,
defective apoptosis, failed ferroptosis, senescence escape, increased OXPHOS,
aberrant stem-cell differentiation, and genomic instability creates a permissive
environment for tumor development. Tissue tropism in LFS reflects which p53
activities are most critical for homeostasis in a given lineage; the most
susceptible compartments are mesenchymal progenitors (sarcomas), mammary
epithelium (HER2+ breast cancer), adrenocortical cells (with cooperating
11p15 LOH/IGF2), neuroepithelium (CNS tumors and choroid plexus carcinoma),
and hematopoietic stem/progenitor cells (leukemia/MDS, especially after
therapy-related stress).
biological_processes:
- preferred_term: cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
downstream:
- target: Aberrant Mesenchymal Stem Cell Differentiation
description: >-
Mesenchymal progenitors are particularly vulnerable; defective osteogenic
differentiation seeds osteosarcoma and soft-tissue sarcoma.
- target: Mammary Epithelial Transformation
description: >-
Premenopausal mammary epithelium is highly susceptible, often acquiring
HER2 amplification on a TP53-null background.
- target: Adrenocortical Tumorigenesis
description: >-
Pediatric adrenocortical cells frequently undergo TP53 LOH together with
11p15 LOH/IGF2 over-expression.
- target: Neuroepithelial Transformation
description: >-
Neural progenitors and choroid plexus epithelium give rise to gliomas,
medulloblastomas, and choroid plexus carcinoma.
- target: Hematopoietic Clonal Expansion
description: >-
TP53-mutant hematopoietic stem/progenitor cells outcompete wild-type
counterparts, especially under genotoxic stress.
- target: Radiation Hypersensitivity
description: >-
p53 deficiency converts ionizing radiation from a curative modality into
a potent inducer of secondary malignancy.
- name: Aberrant Mesenchymal Stem Cell Differentiation
description: >-
Mesenchymal stem cells (MSCs) and their osteoblast progeny are exquisitely
dependent on p53 for proper lineage commitment. In LFS, iPSC-derived MSCs
and osteoblasts show defective osteogenic differentiation, impaired
upregulation of the imprinted long noncoding RNA H19, and reduced expression
of its downstream effector DECORIN (DCN). The resulting expansion of
transformation-competent mesenchymal progenitors gives rise to osteosarcoma
(often in long bones during the adolescent growth spurt) and soft-tissue
sarcomas (rhabdomyosarcoma in childhood, undifferentiated pleomorphic
sarcoma in adults). LFS confers an estimated 500-fold increase in
osteosarcoma incidence relative to the general population.
cell_types:
- preferred_term: mesenchymal stem cell
term:
id: CL:0000134
label: mesenchymal stem cell
biological_processes:
- preferred_term: osteoblast differentiation
modifier: ABNORMAL
term:
id: GO:0001649
label: osteoblast differentiation
evidence:
- reference: PMID:25860607
reference_title: "Modeling familial cancer with induced pluripotent stem cells."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
LFS OBs exhibited impaired upregulation of the imprinted gene H19 during
osteogenesis. Restoration of H19 expression in LFS OBs facilitated
osteoblastic differentiation and repressed tumorigenic potential.
explanation: >-
Patient-derived iPSC modeling of LFS osteosarcoma identifies an
H19/DECORIN axis downstream of mutant p53 that links impaired osteogenic
differentiation to oncogenic transformation, providing the mechanistic
bridge from TP53 mutation to osteosarcoma in LFS.
downstream:
- target: Osteosarcoma
description: >-
Defective osteogenic differentiation of p53-deficient MSCs/osteoblasts
seeds osteosarcoma at sites of high bone turnover.
- target: Soft Tissue Sarcoma
description: >-
Aberrant mesenchymal progenitor differentiation underlies LFS-associated
rhabdomyosarcoma and pleomorphic sarcomas.
- name: Mammary Epithelial Transformation
description: >-
Premenopausal mammary luminal epithelium is the single most cancer-prone
tissue in adult female TP53 carriers, with cumulative breast-cancer
incidence of approximately 49% by age 60 and 54% by age 70. LFS-associated
breast cancers are predominantly invasive ductal carcinomas, frequently
high-grade, hormone-receptor positive (~84% ER/PR+), and HER2-positive in
63% of invasive and 73% of in situ cases - a HER2 enrichment far exceeding
sporadic breast cancer (16-25%). Mechanistically, TP53 loss in mammary
progenitors permits HER2 amplification and escape from oncogene-induced
senescence, while estrogen-driven proliferation amplifies replication stress
in cells lacking the p53 checkpoint.
cell_types:
- preferred_term: luminal epithelial cell of mammary gland
term:
id: CL:0002326
label: luminal epithelial cell of mammary gland
evidence:
- reference: PMID:22392042
reference_title: "Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Sixty three percent of invasive and 73% of in situ carcinomas were
positive for Her2/neu (IHC 3+ or FISH amplified).
explanation: >-
LFS Consortium histopathology of 43 breast tumors from 39 TP53 carriers
establishes the characteristic HER2-positive phenotype of LFS-associated
breast cancer, supporting a model in which TP53 loss permits HER2-driven
transformation in premenopausal mammary epithelium.
downstream:
- target: Breast Cancer
description: >-
TP53 loss in premenopausal mammary epithelium permits HER2 amplification,
hormone-receptor-driven proliferation, and high-grade ductal carcinoma.
- name: Adrenocortical Tumorigenesis
description: >-
The fetal adrenal cortex is one of the most TP53-dependent tissues in
development, and pediatric adrenocortical carcinoma (ACC) is so highly
enriched for germline TP53 variants that any pediatric ACC is an indication
for TP53 testing. ACC tumorigenesis in LFS combines somatic TP53 LOH on
chromosome 17 (~76% of pediatric ACC) with copy-neutral LOH of chromosome
11p with selection against the maternal allele, leading to biallelic IGF2
over-expression in the tumor. The Brazilian R337H founder allele in the
oligomerization domain has attenuated penetrance for most LFS tumors but
confers exceptionally high pediatric ACC risk in southern Brazil and is
responsible for the majority of regional pediatric ACC and choroid plexus
carcinoma cases.
cell_types:
- preferred_term: adrenocortical cell
term:
id: CL:0002097
label: cortical cell of adrenal gland
evidence:
- reference: PMID:25743702
reference_title: "Genomic landscape of paediatric adrenocortical tumours."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Most cases (91%) show loss of heterozygosity (LOH) of chromosome 11p, with
uniform selection against the maternal chromosome
explanation: >-
Whole-genome analysis of pediatric ACC identifies cooperating 11p LOH
with uniparental disomy and IGF2 over-expression as a recurrent second
genomic lesion that combines with TP53 LOH to drive adrenocortical
tumorigenesis in LFS.
downstream:
- target: Adrenocortical Carcinoma
description: >-
Biallelic TP53 inactivation cooperates with 11p15 LOH/IGF2 over-expression
to transform fetal adrenocortical cells.
- name: Neuroepithelial Transformation
description: >-
Neural and neuroepithelial progenitors are highly p53-dependent, and TP53
biallelic inactivation predisposes to a characteristic spectrum of CNS
tumors in LFS: diffuse and high-grade gliomas, medulloblastoma (typically
SHH-activated subtype), and choroid plexus carcinoma (CPC). CPC is so
strongly enriched for germline TP53 mutations that any CPC is an
indication for TP53 testing irrespective of family history. In southern
Brazil, the R337H founder allele drives a markedly elevated CPC incidence.
cell_types:
- preferred_term: neural progenitor cell
term:
id: CL:0011020
label: neural progenitor cell
- preferred_term: choroid plexus epithelial cell
term:
id: CL:0000706
label: choroid plexus epithelial cell
downstream:
- target: Central Nervous System Tumors
description: >-
Loss of p53 in neural progenitors drives gliomas and SHH-medulloblastoma.
- target: Choroid Plexus Carcinoma
description: >-
Loss of p53 in choroid plexus epithelium gives rise to CPC, the most
LFS-specific sentinel CNS tumor.
- name: Hematopoietic Clonal Expansion
description: >-
TP53-mutant hematopoietic stem and progenitor cells (HSPCs) acquire a
competitive advantage over wild-type counterparts, especially under
chemotherapy- or radiation-induced selective pressure. Mutant p53
cooperates with EZH2 to remodel chromatin (increased H3K27me3 at
self-renewal genes), enhancing HSPC self-renewal and blocking
differentiation. In LFS, this manifests as elevated risk of acute
leukemias (both ALL and AML) and therapy-related MDS/AML following
cytotoxic treatment for an earlier primary cancer.
cell_types:
- preferred_term: hematopoietic stem cell
term:
id: CL:0000037
label: hematopoietic stem cell
downstream:
- target: Leukemia
description: >-
p53-mutant HSPC clonal expansion under genotoxic stress drives acute
leukemia and therapy-related MDS/AML in LFS.
- name: Radiation Hypersensitivity
description: >-
p53-deficient cells fail to undergo apoptosis or stable cell-cycle arrest
after ionizing radiation, allowing radiation-damaged cells to survive and
propagate mutations. In LFS, this manifests as shorter latency to second
primary cancer after radiotherapy in children (median 13.3 years with RT
vs 25.1 years without RT, hazard ratio 7.9), with correspondingly worse
survival after the second primary. Modern guidelines therefore recommend
avoidance or attenuation of radiotherapy when alternatives exist (e.g.,
mastectomy preferred over breast-conserving therapy with adjuvant RT) and
pre-treatment TP53 testing in patients with suggestive presentations.
evidence:
- reference: PMID:40059635
reference_title: "Radiotherapy results in decreased time to second cancer in children with Li Fraumeni syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
After radiotherapy for the first cancer diagnosis, median time to second
primary cancer diagnosis was 13.3 years and median survival 9.7 years.
Where no radiotherapy was received, median time to second primary cancer
diagnosis was 25.1 years (χ2 = 14.8, P < .0001; Hazard Ratio = 7.9 [95%
CI = 2.8 to 22.6])
explanation: >-
Retrospective case-series of 47 children with LFS quantifying that
radiotherapy for a first pediatric LFS cancer is associated with a near
8-fold higher hazard of second primary cancer and substantially shorter
time to second cancer, providing direct human evidence that p53
deficiency converts ionizing radiation into a clinically meaningful
driver of subsequent malignancy.
- reference: PMID:32457520
reference_title: "Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
in cancer patients with germline disease-causing TP53 variants,
radiotherapy, and conventional genotoxic chemotherapy contribute to the
development of subsequent primary tumours.
explanation: >-
ERN GENTURIS European consensus guideline anchors radiation
hypersensitivity as a clinically actionable LFS-specific liability and
formally recommends radiotherapy avoidance or attenuation when feasible.
downstream:
- target: Multiple Primary Cancers
description: >-
Radiation-induced second cancers (often in-field sarcomas and breast
cancers) contribute substantially to the multi-primary tumor burden in
treated LFS patients.
phenotypes:
- category: Neoplastic
name: Soft Tissue Sarcoma
frequency: VERY_FREQUENT
description: >-
Soft tissue sarcomas, particularly rhabdomyosarcoma in children and
undifferentiated pleomorphic sarcoma in adults, are core tumors of LFS.
Often present at young ages.
phenotype_term:
preferred_term: Soft tissue sarcoma
term:
id: HP:0030448
label: Soft tissue sarcoma
evidence:
- reference: PMID:26014290
reference_title: "Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers."
supports: SUPPORT
snippet: >-
In childhood, the LFS tumor spectrum was characterized by osteosarcomas,
adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS)
observed in 30%, 27%, 26%, and 23% of the patients, respectively. In adults,
the tumor distribution was characterized by the predominance of breast
carcinomas observed in 79% of the females, and STS observed in 27% of the patients.
explanation: >-
French cohort study of 415 TP53 mutation carriers demonstrates soft tissue
sarcomas are a core tumor type in LFS, occurring in 23% of children and
27% of adults.
- category: Neoplastic
name: Osteosarcoma
frequency: FREQUENT
description: >-
Osteosarcoma is a core tumor of LFS, typically occurring in adolescence
or young adulthood. Often affects the metaphyses of long bones during
the adolescent growth spurt. LFS confers an estimated 500-fold increase
in osteosarcoma incidence relative to the general population.
phenotype_term:
preferred_term: Osteosarcoma
term:
id: HP:0002669
label: Osteosarcoma
onset:
onset_category: JUVENILE
evidence:
- reference: PMID:26014290
reference_title: "Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In childhood, the LFS tumor spectrum was characterized by osteosarcomas,
adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS)
observed in 30%, 27%, 26%, and 23% of the patients, respectively.
explanation: >-
French LFS cohort of 415 TP53 carriers shows osteosarcoma is the most
common pediatric LFS tumor, observed in 30% of childhood cases.
- category: Neoplastic
name: Breast Cancer
frequency: VERY_FREQUENT
description: >-
Premenopausal breast cancer is the dominant adult tumor in female LFS
carriers, with cumulative incidence of approximately 49% by age 60 and
54-79% by age 70. Tumors are predominantly invasive ductal carcinoma,
high grade, hormone-receptor positive (~84% ER/PR+), and HER2-positive
in 63% of invasive and 73% of in situ cases. Median age at diagnosis
is 32 years (range 22-46), substantially younger than sporadic breast
cancer.
phenotype_term:
preferred_term: Breast carcinoma
term:
id: HP:0003002
label: Breast carcinoma
onset:
onset_category: YOUNG_ADULT
evidence:
- reference: PMID:26014290
reference_title: "Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In adults, the tumor distribution was characterized by the predominance of
breast carcinomas observed in 79% of the females, and STS observed in 27%
of the patients.
explanation: >-
French cohort study demonstrates breast cancer is the predominant tumor
type in adult females with LFS, occurring in 79% of affected women.
- reference: PMID:22392042
reference_title: "Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Sixty three percent of invasive and 73% of in situ carcinomas were
positive for Her2/neu (IHC 3+ or FISH amplified).
explanation: >-
LFS Consortium histopathology defines the HER2-enriched phenotype of
LFS-associated breast cancer, supporting use of HER2-directed therapy.
- reference: PMID:27496084
reference_title: "Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Among females, the cumulative incidence rates by age 70 years for breast
cancer, soft tissue sarcoma, brain cancer, and osteosarcoma were 54%,
15%, 6%, and 5%, respectively.
explanation: >-
NCI Li-Fraumeni syndrome cohort of 286 TP53+ individuals provides sex-
stratified cumulative incidence estimates for the major LFS tumors,
anchoring breast cancer as the dominant adult-female phenotype.
- category: Neoplastic
name: Adrenocortical Carcinoma
frequency: FREQUENT
description: >-
Pediatric adrenocortical carcinoma (ACC) is so highly enriched for germline
TP53 mutations that any pediatric ACC is an indication for TP53 testing
irrespective of family history. The Brazilian R337H founder allele in the
p53 oligomerization domain is responsible for a regional 10-15-fold
excess of pediatric ACC in southern Brazil. Tumorigenesis combines TP53
LOH (chromosome 17) with copy-neutral 11p LOH and IGF2 over-expression.
phenotype_term:
preferred_term: Adrenocortical carcinoma
term:
id: HP:0006744
label: Adrenocortical carcinoma
onset:
onset_category: CHILDHOOD
evidence:
- reference: PMID:26014290
reference_title: "Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In childhood, the LFS tumor spectrum was characterized by osteosarcomas,
adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS)
observed in 30%, 27%, 26%, and 23% of the patients, respectively.
explanation: >-
Pediatric ACC accounts for 27% of childhood LFS tumors in the French
cohort, anchoring ACC as a core childhood phenotype of the syndrome.
- reference: PMID:25743702
reference_title: "Genomic landscape of paediatric adrenocortical tumours."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
TP53 mutations and chromosome 17 LOH with selection against wild-type TP53
are observed in 28 ACTs (76%)
explanation: >-
Genome-wide profiling identifies TP53 LOH as the dominant second-hit
event in pediatric ACC, mechanistically anchoring this phenotype to the
LFS pathograph.
- category: Neoplastic
name: Central Nervous System Tumors
frequency: FREQUENT
description: >-
Brain tumors including diffuse and high-grade gliomas, choroid plexus
carcinoma, and medulloblastoma (typically SHH-activated) occur with
increased frequency. Choroid plexus carcinoma in childhood is sufficiently
specific for LFS that any CPC is an indication for TP53 testing. Cumulative
risk by age 70 is approximately 6% (females) and 19% (males) of LFS
carriers.
phenotype_term:
preferred_term: Malignant neoplasm of the central nervous system
term:
id: HP:0100836
label: Malignant neoplasm of the central nervous system
evidence:
- reference: PMID:26014290
reference_title: "Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In childhood, the LFS tumor spectrum was characterized by osteosarcomas,
adrenocortical carcinomas (ACC), CNS tumors, and soft tissue sarcomas (STS)
observed in 30%, 27%, 26%, and 23% of the patients, respectively.
explanation: >-
CNS tumors account for 26% of pediatric LFS tumors in the French TP53
carrier cohort.
- category: Neoplastic
name: Choroid Plexus Carcinoma
frequency: OCCASIONAL
description: >-
Choroid plexus carcinoma (CPC) is a rare aggressive pediatric brain tumor
so highly enriched for germline TP53 pathogenic variants (approximately
50% of CPC patients) that any childhood CPC is an indication for TP53
testing irrespective of family history. In southern Brazil, the R337H
founder allele drives a markedly elevated CPC incidence, accounting for
~63% of regional pediatric CPC cases. CPC is included with adrenocortical
carcinoma and SHH-medulloblastoma among the highest-specificity sentinel
tumors used in modified Chompret criteria.
phenotype_term:
preferred_term: Choroid plexus carcinoma
term:
id: HP:0030392
label: Choroid plexus carcinoma
onset:
onset_category: CHILDHOOD
- category: Neoplastic
name: Leukemia
frequency: OCCASIONAL
description: >-
Acute leukemias (both ALL and AML) occur at increased frequency in LFS
patients, often at young ages. Therapy-related MDS/AML is an additional
risk after cytotoxic treatment of an earlier primary cancer, reflecting
expansion of pre-existing TP53-mutant hematopoietic clones under selective
pressure from chemotherapy and radiation.
phenotype_term:
preferred_term: Acute leukemia
term:
id: HP:0002488
label: Acute leukemia
- category: Neoplastic
name: Multiple Primary Cancers
frequency: FREQUENT
description: >-
Approximately 43% of LFS carriers who develop a first cancer go on to
develop one or more additional independent primary cancers during their
lifetime; the average number of tumors per affected carrier is ~1.7,
and the average age-specific risk of a second cancer is comparable to
that of the first. This metachronous/synchronous multi-primary pattern
is a characteristic feature distinguishing LFS from sporadic disease and
a major motivation for lifelong surveillance and radiation/genotoxin
avoidance.
phenotype_term:
preferred_term: Multiple primary malignant neoplasms
term:
id: HP:0002664
label: Neoplasm
notes: >-
The HPO does not currently provide a discrete term for "multiple primary
cancers" as a syndromic phenotype; the closest available descendants
(HP:0007606 Multiple cutaneous malignancies; HP:0033714 Multiple
meningiomas) are anatomically restricted. The root term HP:0002664
Neoplasm is therefore retained as the best available binding while the
descriptor's preferred_term carries the more specific clinical concept.
evidence:
- reference: PMID:26014290
reference_title: "Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The 322 affected carriers developed 552 tumors, and 43% had developed
multiple malignancies. The mean age of first tumor onset was 24.9 years,
41% having developed a tumor by age 18.
explanation: >-
Large French cohort demonstrates that 43% of LFS patients develop multiple
malignancies, with average 1.7 tumors per affected carrier.
- reference: PMID:27496084
reference_title: "Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Approximately 49% of those with 1 cancer developed at least another
cancer after a median of 10 years. The average age-specific risk of
developing a second cancer was comparable to that of developing a first
cancer.
explanation: >-
Independent NCI Li-Fraumeni syndrome cohort confirms that nearly half of
affected carriers develop a second primary cancer with hazard comparable
to that of the first, anchoring the multi-primary phenotype as a
hallmark of the syndrome.
biochemical:
- name: TP53 Genetic Testing
notes: >-
Molecular testing of TP53 identifies germline pathogenic variants including
missense mutations (especially in the DNA-binding domain), nonsense mutations,
frameshift mutations, and splice site variants. Certain mutations (R175H,
R248W, R273H) have dominant-negative effects.
genetic:
- name: TP53
association: Germline Loss-of-Function Mutations
inheritance:
- name: Autosomal Dominant
notes: >-
TP53 (17p13.1) encodes the p53 tumor suppressor protein. Germline pathogenic
variants cause LFS with high but incomplete penetrance. Most mutations are
missense variants in the DNA-binding domain (exons 5-8). Some mutations
(R175H, R248Q, R248W, R273H, R273C) have dominant-negative effects beyond
simple loss of function. The Brazilian founder mutation R337H, located in
the oligomerization domain (exon 10), has attenuated overall penetrance but
is responsible for the majority of pediatric adrenocortical carcinoma and
choroid plexus carcinoma cases in southern Brazil. De novo TP53 variants
account for an estimated 7-20% of LFS cases (ERN GENTURIS guideline). The
expanded "heritable TP53-related cancer syndrome" (hTP53rc) concept now
encompasses attenuated and non-classical presentations identified
increasingly via genome-first ascertainment. Updated maximum-likelihood
pedigree-based penetrance estimates (Fortuno 2024) place cumulative cancer
risk by age 50 at ~92% in females and ~60% in males, with female cumulative
breast cancer risk of ~63% by age 50. Genetic modifiers that accelerate age
at first cancer in TP53 carriers include the MDM2 SNP309 G allele
(rs2279744), which raises MDM2 levels and dampens residual p53 function,
and the TP53 PIN3 16-bp duplication; combined with the TP53 codon-72 Arg
allele these modifiers can shift age at onset by approximately a decade.
evidence:
- reference: PMID:26014290
reference_title: "Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The mean age of tumor onset was statistically different (P < .05) between
carriers harboring dominant-negative missense mutations (21.3 years) and
those with all types of loss of function mutations (28.5 years) or genomic
rearrangements (35.8 years). Affected children, except those with ACC,
harbored mostly dominant-negative missense mutations.
explanation: >-
Clinical gradient of germline TP53 mutations demonstrates that dominant-negative
missense mutations cause earlier tumor onset (21.3 years) compared to loss-of-function
mutations (28.5 years), supporting mutation-specific phenotype stratification.
- reference: PMID:32457520
reference_title: "Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the penetrance of germline disease-causing TP53 variants is variable,
depending both on the type of variant (dominant-negative variants being
associated with a higher cancer risk) and on modifying factors
explanation: >-
ERN GENTURIS European consensus guideline confirms that variant class
(dominant-negative > LOF > rearrangements) and additional modifiers drive
penetrance variability, anchoring the genotype-phenotype gradient
observed in clinical practice.
- reference: DOI:10.1200/PO.23.00453
reference_title: "Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The cumulative risk of any cancer type by age 50 years was 92.4% (95% CI,
82.2 to 98.3) for females and 59.7% (95% CI, 39.9 to 81.3) for males.
Females had a 63.3% (95% CI, 35.6 to 90.1) cumulative risk of developing
breast cancer by age 50 years.
explanation: >-
Maximum-likelihood pedigree analysis of 146 TP53-positive families (4,028
individuals) provides ascertainment-corrected sex-specific penetrance
estimates and additionally identifies elevated lifetime risk for
colorectal, gastric, lung, pancreatic, and ovarian cancers beyond the
classical LFS spectrum.
- reference: CGGV:assertion_78494aba-bb52-4b33-bf1d-ebbb5374df4b-2024-03-22T170000.000Z
reference_title: "TP53 / Li-Fraumeni syndrome (Definitive)"
supports: SUPPORT
evidence_source: OTHER
snippet: "TP53 | HGNC:11998 | Li-Fraumeni syndrome | MONDO:0018875 | AD | Definitive"
explanation: ClinGen classifies the TP53-Li-Fraumeni syndrome gene-disease relationship as definitive with autosomal dominant inheritance.
treatments:
- name: Toronto Protocol Cancer Surveillance
description: >-
Lifelong intensive cancer surveillance (Toronto Protocol) including annual
whole-body MRI, annual brain MRI (with gadolinium for the first scan,
non-contrast thereafter), annual breast MRI alternating every 6 months
with whole-body MRI in adult women, abdominal/pelvic ultrasound every 3-6
months in children for adrenocortical carcinoma surveillance, semi-annual
physical examination, and biochemical markers (e.g., serum/urine steroids
in childhood). Surveillance should begin as soon as TP53 carrier status is
known and continue lifelong. Prospective comparative data demonstrate a
near-doubling of 5-year overall survival in surveillance vs non-surveillance
arms (88.8% vs 59.6%).
treatment_term:
preferred_term: cancer screening
term:
id: MAXO:0000126
label: cancer screening
target_phenotypes:
- preferred_term: Soft tissue sarcoma
term:
id: HP:0030448
label: Soft tissue sarcoma
- preferred_term: Osteosarcoma
term:
id: HP:0002669
label: Osteosarcoma
- preferred_term: Breast carcinoma
term:
id: HP:0003002
label: Breast carcinoma
- preferred_term: Adrenocortical carcinoma
term:
id: HP:0006744
label: Adrenocortical carcinoma
- preferred_term: Malignant neoplasm of the central nervous system
term:
id: HP:0100836
label: Malignant neoplasm of the central nervous system
evidence:
- reference: PMID:28572266
reference_title: "Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the panel recommends adoption of a modified version of the "Toronto protocol"
that includes a combination of physical exams, blood tests, and imaging.
explanation: >-
AACR expert panel consensus recommends the Toronto Protocol surveillance
approach for all LFS patients as soon as diagnosis is established.
- reference: PMID:27501770
reference_title: "Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
5 year overall survival was 88·8% (95% CI 78·7-100) in the surveillance
group and 59·6% (47·2-75·2) in the non-surveillance group (p=0·0132).
explanation: >-
Eleven-year follow-up of the original Toronto Protocol prospective cohort
demonstrates that intensive imaging-based surveillance approximately
halves cancer-specific mortality at 5 years, providing the strongest
evidence base for lifelong WB-MRI/brain-MRI surveillance in LFS.
- reference: PMID:32457520
reference_title: "Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
whole-body MRI (WBMRI) allows early detection of tumours in variant
carriers
explanation: >-
ERN GENTURIS European consensus guideline endorses WBMRI as the
cornerstone radiation-free surveillance modality for LFS/hTP53rc.
- name: Risk-Reducing Bilateral Mastectomy
description: >-
Prophylactic bilateral mastectomy may be considered for women with LFS
given the extremely high lifetime breast cancer risk (cumulative incidence
~49% by age 60, ~54-79% by age 70) and the additional radiation hazards
associated with breast-conserving therapy in TP53 carriers. Decision
requires individualized counseling about risks and benefits, including
cosmetic outcome and the elimination of future need for adjuvant breast
irradiation.
treatment_term:
preferred_term: prophylactic mastectomy
term:
id: MAXO:0000004
label: surgical procedure
target_phenotypes:
- preferred_term: Breast carcinoma
term:
id: HP:0003002
label: Breast carcinoma
target_mechanisms:
- target: Mammary Epithelial Transformation
description: >-
Surgical removal of mammary epithelium eliminates the principal tissue at
risk for HER2-driven, TP53-deficient transformation in adult female
carriers.
- name: HER2-Directed Therapy
description: >-
Trastuzumab and other HER2-directed agents are indicated for LFS-associated
breast cancers given the high prevalence of HER2 amplification (63% of
invasive and 73% of in situ ductal carcinomas in LFS women). HER2-directed
therapy has substantially improved outcomes for LFS-associated breast
cancer and is part of standard adjuvant care alongside radiation-sparing
surgical management.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: trastuzumab
term:
id: NCIT:C1647
label: Trastuzumab
target_phenotypes:
- preferred_term: Breast carcinoma
term:
id: HP:0003002
label: Breast carcinoma
evidence:
- reference: PMID:22392042
reference_title: "Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Sixty three percent of invasive and 73% of in situ carcinomas were
positive for Her2/neu (IHC 3+ or FISH amplified).
explanation: >-
Pathology characterization of 43 LFS-associated breast cancers establishes
HER2 amplification as a dominant feature, providing the rationale for
anti-HER2 therapy as a core component of LFS breast cancer management.
- name: Genetic Counseling and Cascade Testing
description: >-
Genetic counseling is essential for affected families to discuss
inheritance, testing of at-risk relatives, reproductive options
(preimplantation genetic diagnosis), psychological support, and
surveillance enrollment. Cascade testing of first-degree relatives is
recommended after a proband is identified, including pediatric testing
when the variant is associated with childhood cancer risk. TP53 testing
should ideally be performed before initiation of cancer-directed therapy
to inform radiation- and genotoxin-sparing treatment choices.
treatment_term:
preferred_term: genetic counseling
term:
id: MAXO:0000079
label: genetic counseling
- name: Radiation Avoidance
description: >-
Radiation therapy should be avoided or attenuated when alternatives exist
in LFS patients due to substantially elevated risk of radiation-induced
secondary malignancies and shortened latency to second primary cancers.
Diagnostic imaging should preferentially use MRI/ultrasound in lieu of CT
or mammography. For breast cancer, mastectomy is generally preferred over
lumpectomy plus adjuvant radiotherapy. TP53 testing is recommended before
treatment initiation in any newly diagnosed cancer with suggestive
phenotype to inform radiation-sparing management.
notes: >-
p53 is critical for radiation-induced apoptosis and cell cycle arrest.
LFS patients are exquisitely sensitive to radiation-induced carcinogenesis.
target_mechanisms:
- target: Radiation Hypersensitivity
description: >-
Avoiding ionizing radiation circumvents the p53-deficient cell's failure
to apoptose or arrest after radiation-induced DNA damage, thereby
preventing in-field radiation-induced second primaries.
evidence:
- reference: PMID:32457520
reference_title: "Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
in cancer patients with germline disease-causing TP53 variants,
radiotherapy, and conventional genotoxic chemotherapy contribute to the
development of subsequent primary tumours. It is critical to perform
TP53 testing before the initiation of treatment in order to avoid in
carriers, if possible, radiotherapy and genotoxic chemotherapies.
explanation: >-
ERN GENTURIS European consensus guideline formally recommends radiation
and genotoxic chemotherapy avoidance whenever feasible in TP53 carriers
and pre-treatment TP53 testing in patients with suspicious presentations.
- name: Metformin Chemoprevention (Investigational)
description: >-
Metformin is being evaluated as a precision-prevention agent in adults with
LFS in the open-label randomized phase II MILI trial (224 participants
randomized to oral metformin plus annual MRI surveillance vs surveillance
alone; primary endpoint 5-year cumulative cancer-free survival). The
rationale is the LFS-specific bioenergetic shift toward elevated
mitochondrial oxidative phosphorylation, which can be pharmacologically
attenuated by metformin (mitochondrial complex I inhibition, AMPK
activation, mTORC1 suppression). Mouse-model and human pilot data show
metformin reduces mitochondrial activity and delays tumorigenesis. This
is an experimental intervention; it is not yet standard of care.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: metformin
term:
id: CHEBI:6801
label: metformin
target_mechanisms:
- target: Increased Mitochondrial Oxidative Phosphorylation
description: >-
Metformin inhibits mitochondrial complex I and activates AMPK, partially
reversing the LFS-specific OXPHOS up-regulation that promotes tumor
development.
evidence:
- reference: PMID:27869650
reference_title: "Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
genetic or pharmacologic disruption of mitochondrial respiration improves
cancer-free survival
explanation: >-
Mouse model and human pilot data demonstrating that metformin extends
cancer-free survival by attenuating LFS-associated mitochondrial
respiration, providing the mechanistic rationale for the MILI prevention
trial.
- reference: DOI:10.1186/s13063-024-07929-w
reference_title: "Cancer precision-prevention trial of metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocol."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Metformin in adults with Li-Fraumeni syndrome (MILI) is a
Precision-Prevention phase II open-labelled unblinded randomised clinical
trial in which 224 adults aged ≥ 16 years with LFS are randomised 1:1 to
oral metformin (up to 2 mg daily) plus annual MRI surveillance or annual
MRI surveillance alone for up to 5 years.
explanation: >-
Phase II precision-prevention trial protocol formally testing metformin
chemoprevention in adult LFS carriers, transitioning the OXPHOS-targeting
hypothesis from preclinical models to a randomized clinical evaluation.
- name: Cell-Free DNA (Liquid Biopsy) Surveillance (Investigational)
description: >-
Multimodal cell-free DNA assays integrating targeted gene panels, shallow
whole-genome sequencing, and methylation profiling have demonstrated
proof-of-principle for early cancer detection in LFS, with positive
predictive value 67.6% and negative predictive value 96.5% in a
longitudinal cohort of 89 carriers, and detection of cancer-associated
signal months before conventional imaging diagnosis. cfDNA surveillance
is being developed as a complement to, not replacement for, the Toronto
Protocol; it is not yet incorporated in standard guidelines.
treatment_term:
preferred_term: cancer screening
term:
id: MAXO:0000126
label: cancer screening
evidence:
- reference: DOI:10.1158/2159-8290.CD-23-0456
reference_title: "Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Multimodal analysis increased our detection rate in patients with an
active cancer diagnosis over uni-modal analysis and was able to detect
cancer-associated signal(s) in carriers prior to diagnosis with
conventional screening (positive predictive value = 67.6%, negative
predictive value = 96.5%).
explanation: >-
Longitudinal multimodal cfDNA study in TP53 carriers demonstrates that
liquid biopsy can detect cancer-associated signals earlier than
conventional imaging, supporting development of cfDNA as an adjunct
surveillance modality in LFS.
clinical_trials:
- name: NCT01737255
phase: NOT_APPLICABLE
status: COMPLETED
description: >-
SIGNIFY: An exploratory whole-body MRI study evaluating MRI-based cancer
screening in TP53 mutation carriers compared to population controls,
with secondary endpoints on incidental findings and the psychological
impact of surveillance.
evidence:
- reference: clinicaltrials:NCT01737255
supports: SUPPORT
snippet: >-
This study is aimed at exploring the use of whole body MRI for early
cancer detection in TP53 mutation carriers and population controls,
with the hypothesis that more cancers will be detected in the TP53
mutation carrier group.
explanation: >-
Foundational case-control evaluation of whole-body MRI as a surveillance
modality in LFS, complementing the Toronto Protocol surveillance
treatment.
- name: NCT02950987
phase: NOT_APPLICABLE
status: ACTIVE_NOT_RECRUITING
description: >-
Single-group interventional study at Dana-Farber assessing annual whole-
body MRI for primary tumor detection in children and adults with LFS and
other cancer predisposition syndromes, with annual return/retention
endpoints across four scans.
evidence:
- reference: clinicaltrials:NCT02950987
supports: SUPPORT
snippet: >-
This study is evaluating Whole Body MRI as a possible screening tool
to diagnose cancer for people with LFS and other inherited cancer
predisposition syndromes.
explanation: >-
Pediatric+adult WB-MRI surveillance trial that anchors the cancer-
detection-rate evidence base for the Toronto Protocol approach in LFS.
- name: NCT03176836
phase: NOT_APPLICABLE
status: ENROLLING_BY_INVITATION
description: >-
Pediatric LFS imaging study at SickKids evaluating novel MRI-based
techniques (including STIR/DWI and conditional PET-MRI) to characterize
sensitivity for small tumors and specificity for distinguishing malignant
from benign findings during surveillance.
evidence:
- reference: clinicaltrials:NCT03176836
supports: SUPPORT
snippet: >-
This project will use novel techniques utilizing magnetic resonance
imaging (MRI) to determine how sensitive they are at detecting very
small tumors and how specific they are in terms of distinguishing
malignant tumors from benign tumors.
explanation: >-
Pilot imaging-trait study supporting refinement of WB-MRI surveillance
protocols and reduction of false-positive findings in pediatric LFS
surveillance.
- name: NCT04367246
phase: NOT_APPLICABLE
status: RECRUITING
description: >-
Prospective TP53/LFS biobank establishing a clinical database and
biospecimen collection (including ctDNA aims) at the Abramson Cancer
Center, supporting genotype-phenotype studies, biomarker-driven
surveillance, and precision-medicine research in TP53-associated tumors.
evidence:
- reference: clinicaltrials:NCT04367246
supports: SUPPORT
snippet: >-
In order to study these important issues in LFS, this protocol will
establish a TP53 Clinical Database and Biobank.
explanation: >-
Biobank/biospecimen study underpinning the cfDNA early-detection and
genotype-phenotype work that motivates emerging precision-surveillance
strategies in LFS.
disease_term:
preferred_term: Li-Fraumeni syndrome
term:
id: MONDO:0018875
label: Li-Fraumeni syndrome
references:
- reference: PMID:20301488
title: "Li-Fraumeni Syndrome."
tags:
- GeneReviews
findings: []
Li‑Fraumeni syndrome (LFS) is a classical, highly penetrant hereditary cancer predisposition syndrome characterized by early onset cancers and an unusually broad tumor spectrum, most commonly driven by germline pathogenic variants in TP53. (giovino2024newparadigmsin pages 2-4, sanchezheras2023seomclinicalguideline pages 1-2)
Because many TP53‑associated cancer presentations do not meet “classic” LFS family-history patterns, European and national guidelines describe a broader umbrella entity, heritable TP53‑related cancer syndrome (hTP53rc). (sanchezheras2023seomclinicalguideline pages 1-2, frebourg2020guidelinesforthe pages 1-2)
This report synthesizes aggregated disease-level resources (international/national guidelines, systematic reviews, cohort penetrance analyses, genome-first biobank studies) and human clinical research (cfDNA surveillance proof-of-principle; MRI surveillance studies) rather than EHR-only single-institution datasets. (fortuno2024cancerrisksassociated pages 1-2, temperley2024wholebodymriscreening pages 11-13, wong2024earlycancerdetection pages 1-3, andrade2024genomefirstapproachof pages 2-3)
Genetic etiology (primary): heterozygous germline pathogenic/likely pathogenic variants in TP53 cause LFS/hTP53rc. (sanchezheras2023seomclinicalguideline pages 1-2, frebourg2020guidelinesforthe pages 1-2)
De novo variants: de novo TP53 variants are estimated at ~7–20% of cases in ERN GENTURIS guidance, supporting testing even without strong family history. (frebourg2020guidelinesforthe pages 1-2)
No proven licensed chemopreventive agents exist for LFS/hTP53rc in current standard care; chemoprevention is an active research area. (dixonzegeye2024cancerprecisionpreventiontrial pages 1-2)
Guidelines and reviews consistently describe a “core” LFS tumor spectrum that includes: - Premenopausal/early-onset breast cancer - Soft tissue sarcoma - Osteosarcoma - Central nervous system (CNS) tumors - Adrenocortical carcinoma (ACC) (sanchezheras2023seomclinicalguideline pages 1-2, frebourg2020guidelinesforthe pages 1-2)
Rare/highly suggestive tumors for TP53 testing include choroid plexus carcinoma, hypodiploid ALL, anaplastic embryonal rhabdomyosarcoma, SHH medulloblastoma, and jaw osteosarcoma. (sanchezheras2023seomclinicalguideline pages 1-2, frebourg2020guidelinesforthe pages 4-5)
Quality-of-life impact is primarily mediated by repeated screening, follow-up of incidental findings, anxiety, and (in pediatrics) sedation requirements for MRI-based surveillance. (temperley2024wholebodymriscreening pages 11-13, kumamoto2021medicalguidelinesfor pages 1-2)
Tumor phenotypes (HPO broadly): - Breast carcinoma — HP:0003002 - Soft tissue sarcoma — HP:0100242 - Osteosarcoma — HP:0006731 - Brain neoplasm — HP:0004375 - Adrenocortical carcinoma — HP:0006746 Additional TP53-associated rare tumors: - Choroid plexus carcinoma — HP:0030858 - Acute lymphoblastic leukemia — HP:0006728
A large genome-first analysis across EHR-linked cohorts (414,824 individuals) found prevalence estimates that depend on cohort selection and potential CH confounding: - UK Biobank (after excluding hematologic cancers): ~1:10,438 - Geisinger (after excluding hematologic cancers): ~1:3,790 - PMBB (after excluding hematologic cancers): ~1:2,983 (andrade2024genomefirstapproachof pages 2-3, andrade2024genomefirstapproachof pages 3-4)
A heterogeneity-focused review summarizes evidence that age of onset can be modified by polymorphisms including: - MDM2 SNP309 (G allele associated with earlier tumor onset) - TP53 PIN3 polymorphism (heterozygotes associated with earlier onset) - TP53 p.Pro72Arg polymorphism (Arg allele associated with earlier onset) (gargallo2020li–fraumenisyndromeheterogeneity pages 2-4)
Epigenetic/noncoding regulators (candidate modifiers) include multiple miRNAs (e.g., miR‑34 family) and lncRNAs (e.g., Wrap53), as well as telomere shortening and other factors. (gargallo2020li–fraumenisyndromeheterogeneity pages 7-8)
Mechanistic reviews propose that altered regulation of TP53 expression via miRNAs/lncRNAs and DNA methylation pathways may contribute to intrafamilial variability. (gargallo2020li–fraumenisyndromeheterogeneity pages 7-8)
Direct, quantitative environmental risk factors for cancer incidence in TP53 carriers were not established in the retrieved primary sources. However, guideline and mechanistic literature emphasize minimizing iatrogenic radiation exposure (diagnostic CT/mammography where alternatives exist, and radiotherapy where feasible) due to subsequent primary tumor risk. (frebourg2020guidelinesforthe pages 1-2, sanchezheras2023seomclinicalguideline pages 4-6)
No infectious causal agent is implicated for LFS; it is a genetic predisposition syndrome.
GO Biological Process (examples): - DNA damage response, signal transduction by p53 class mediator — GO:0030330 - Regulation of apoptotic process — GO:0042981 - Cell cycle arrest — GO:0007050 - Regulation of transcription by RNA polymerase II — GO:0006357
CL cell types (examples relevant to cancers in spectrum): - Hematopoietic stem cell — CL:0000037 - Epithelial cell (breast) — CL:0000066 - Osteoblast — CL:0000062 - Glial cell — CL:0000121
UBERON anatomical structures (examples): - Breast — UBERON:0000310 - Brain — UBERON:0000955 - Adrenal gland cortex — UBERON:0002367 - Bone — UBERON:0002481
LFS/hTP53rc is a systemic predisposition affecting multiple organ systems due to ubiquitous TP53 function; clinically, tumors commonly arise in breast, bone/soft tissues, CNS, and adrenal cortex. (sanchezheras2023seomclinicalguideline pages 1-2, frebourg2020guidelinesforthe pages 1-2)
LFS is typically autosomal dominant. (dixonzegeye2024cancerprecisionpreventiontrial pages 1-2, kumamoto2021medicalguidelinesfor pages 1-2)
The SEOM guideline specifies modified Chompret testing indications, including early-onset core cancers, multiple primaries, and specific rare pediatric tumors; it also recommends testing after a second primary tumor arising in a prior radiotherapy field following an early core tumor. (sanchezheras2023seomclinicalguideline pages 2-4)
Guidelines emphasize MRI/ultrasound-based surveillance. A SEOM guideline-derived schedule is summarized in the artifact below (children vs adults, imaging intervals). (sanchezheras2023seomclinicalguideline pages 4-6)
Whole-body MRI evidence (2024 update): A 2024 systematic review/meta-analysis pooling eight studies (506 carriers) found a pooled WB‑MRI cancer detection rate of 7% (95% CI 5–10%) and 36/506 (7.1%) new cancers diagnosed. (temperley2024wholebodymriscreening pages 11-13, temperley2024wholebodymriscreening pages 9-11)
Harms/limitations: WB‑MRI can yield incidental lesions and anxiety, lacks universal protocol standardization, and lacks cost-effectiveness evaluation in included studies. (temperley2024wholebodymriscreening pages 11-13)
A 2024 Cancer Discovery report describes multimodal cfDNA (targeted sequencing, shallow WGS, methylation) in TP53 carriers under Toronto Protocol surveillance. It reports multimodal performance metrics (PPV/NPV) and examples of detection months-to-years before clinical diagnosis (e.g., methylation signal ~20 months before osteosarcoma), supporting liquid biopsy as a potential adjunct to annual imaging. (wong2024earlycancerdetection pages 1-3, wong2024earlycancerdetection pages 9-11, wong2024earlycancerdetection pages 8-9)
The SEOM guideline reports that Toronto Protocol surveillance improved 5‑year survival (88% vs 59.6%). (sanchezheras2023seomclinicalguideline pages 2-4)
Guidelines emphasize risk of multiple primaries and treatment-related subsequent primaries, motivating radiation-sparing management and lifelong surveillance. (frebourg2020guidelinesforthe pages 1-2, kumamoto2021medicalguidelinesfor pages 1-2)
LFS is a cancer predisposition syndrome rather than a single tumor entity; treatment is cancer-type specific, but management is strongly influenced by TP53 carrier status.
Suggested MAXO terms (examples): - Cancer surveillance — MAXO:0000535 - Whole-body magnetic resonance imaging — MAXO:0001064 (imaging procedure) - Prophylactic mastectomy — MAXO:0001103 - Genetic counseling — MAXO:0000079
No naturally occurring “Li‑Fraumeni syndrome” diagnosis in non-human species was retrieved from the accessed texts. Mechanistic conservation of TP53 biology is strong across vertebrates, and TP53-driven tumor predisposition is widely modeled experimentally (see §15).
| Metric | Value | Population/Context | Source (short) | URL | Publication date |
|---|---|---|---|---|---|
| Lifetime cancer risk, males | ~70% | Classical Li-Fraumeni syndrome / germline TP53 pathogenic variant carriers | Dixon-Zegeye et al. 2024 (dixonzegeye2024cancerprecisionpreventiontrial pages 1-2) | https://doi.org/10.1186/s13063-024-07929-w | 2024-02 |
| Lifetime cancer risk, females | ~100% | Classical Li-Fraumeni syndrome / germline TP53 pathogenic variant carriers | Dixon-Zegeye et al. 2024 (dixonzegeye2024cancerprecisionpreventiontrial pages 1-2) | https://doi.org/10.1186/s13063-024-07929-w | 2024-02 |
| Lifetime cancer risk, males | ~75% | TP53 pathogenic variant carriers; guideline estimate | Kumamoto et al. 2021 (kumamoto2021medicalguidelinesfor pages 1-2) | https://doi.org/10.1007/s10147-021-02011-w | 2021-10 |
| Lifetime cancer risk, females | >90% to nearly 100% | TP53 pathogenic variant carriers; review/guideline estimates | Giovino et al. 2024; Kumamoto et al. 2021 (giovino2024newparadigmsin pages 2-4, kumamoto2021medicalguidelinesfor pages 1-2) | https://doi.org/10.1101/cshperspect.a041584 ; https://doi.org/10.1007/s10147-021-02011-w | 2024-05; 2021-10 |
| Cumulative risk of any cancer by age 50, females | 92.4% (95% CI 82.2–98.3) | TP53-positive families; maximum-likelihood pedigree analysis | Fortuno et al. 2024 (fortuno2024cancerrisksassociated pages 1-2) | https://doi.org/10.1200/PO.23.00453 | 2024-02 |
| Cumulative risk of any cancer by age 50, males | 59.7% (95% CI 39.9–81.3) | TP53-positive families; maximum-likelihood pedigree analysis | Fortuno et al. 2024 (fortuno2024cancerrisksassociated pages 1-2) | https://doi.org/10.1200/PO.23.00453 | 2024-02 |
| Cumulative breast cancer risk by age 50, females | 63.3% (95% CI 35.6–90.1) | Female TP53 carriers | Fortuno et al. 2024 (fortuno2024cancerrisksassociated pages 1-2) | https://doi.org/10.1200/PO.23.00453 | 2024-02 |
| Prevalence of P/LP germline TP53 variants, UK Biobank | 1:10,438 | Genome-first cohort after excluding hematologic-cancer/confounded cases | de Andrade et al. 2024 (andrade2024genomefirstapproachof pages 2-3, andrade2024genomefirstapproachof pages 3-4) | https://doi.org/10.1016/j.xhgg.2023.100242 | 2024-01 |
| Prevalence of P/LP germline TP53 variants, Geisinger | 1:3,790 | Genome-first cohort after excluding hematologic-cancer/confounded cases | de Andrade et al. 2024 (andrade2024genomefirstapproachof pages 2-3, andrade2024genomefirstapproachof pages 3-4) | https://doi.org/10.1016/j.xhgg.2023.100242 | 2024-01 |
| Prevalence of P/LP germline TP53 variants, PMBB | 1:2,983 | Genome-first cohort after excluding hematologic-cancer/confounded cases | de Andrade et al. 2024 (andrade2024genomefirstapproachof pages 2-3, andrade2024genomefirstapproachof pages 3-4) | https://doi.org/10.1016/j.xhgg.2023.100242 | 2024-01 |
| Whole-body MRI pooled cancer detection rate | 7% (95% CI 5–10) | 8 studies; 506 germline TP53 carriers | Temperley et al. 2024 (temperley2024wholebodymriscreening pages 11-13, temperley2024wholebodymriscreening pages 9-11) | https://doi.org/10.3390/jcm13051223 | 2024-02 |
| New cancers diagnosed on WB-MRI | 36/506 (7.1%) | Systematic review of germline TP53 carriers | Temperley et al. 2024 (temperley2024wholebodymriscreening pages 11-13) | https://doi.org/10.3390/jcm13051223 | 2024-02 |
| WB-MRI false-positive rate | 42.5% | Baseline WB-MRI screening performance in guideline summary | SEOM guideline 2023 (sanchezheras2023seomclinicalguideline pages 4-6) | https://doi.org/10.1007/s12094-023-03202-9 | 2023-05 |
| Brain MRI sensitivity | ~60% | Baseline brain MRI screening performance in TP53 carriers | SEOM guideline 2023 (sanchezheras2023seomclinicalguideline pages 4-6) | https://doi.org/10.1007/s12094-023-03202-9 | 2023-05 |
| Brain MRI specificity | ~80% | Baseline brain MRI screening performance in TP53 carriers | SEOM guideline 2023 (sanchezheras2023seomclinicalguideline pages 4-6) | https://doi.org/10.1007/s12094-023-03202-9 | 2023-05 |
| Brain MRI baseline detection range | 1.7%–8.6% | Baseline brain MRI screening yield | SEOM guideline 2023 (sanchezheras2023seomclinicalguideline pages 4-6) | https://doi.org/10.1007/s12094-023-03202-9 | 2023-05 |
| Brain MRI cumulative detection | 13.6% | Cumulative detection during surveillance | SEOM guideline 2023 (sanchezheras2023seomclinicalguideline pages 4-6) | https://doi.org/10.1007/s12094-023-03202-9 | 2023-05 |
| Toronto Protocol 5-year survival | 88% vs 59.6% | Surveillance cohort vs non-surveillance comparator | SEOM guideline 2023 (sanchezheras2023seomclinicalguideline pages 2-4) | https://doi.org/10.1007/s12094-023-03202-9 | 2023-05 |
| cfDNA multimodal PPV | 67.6% | Longitudinal multimodal cfDNA analysis in LFS | Wong et al. 2024 (wong2024earlycancerdetection pages 1-3) | https://doi.org/10.1158/2159-8290.CD-23-0456 | 2024-10 |
| cfDNA multimodal NPV | 96.5% | Longitudinal multimodal cfDNA analysis in LFS | Wong et al. 2024 (wong2024earlycancerdetection pages 1-3) | https://doi.org/10.1158/2159-8290.CD-23-0456 | 2024-10 |
| cfDNA PPV in clinically cancer-free TP53 carriers | 54.2% (26/48) | Cancer-free samples/individuals with cancer-associated cfDNA signal | Wong et al. 2024 (wong2024earlycancerdetection pages 8-9, wong2024earlycancerdetection pages 11-12) | https://doi.org/10.1158/2159-8290.CD-23-0456 | 2024-10 |
| cfDNA NPV in clinically cancer-free TP53 carriers | 95.4% (41/43) | Cancer-free samples/individuals without cancer-associated cfDNA signal | Wong et al. 2024 (wong2024earlycancerdetection pages 8-9, wong2024earlycancerdetection pages 11-12) | https://doi.org/10.1158/2159-8290.CD-23-0456 | 2024-10 |
| cfDNA false-positive rate, sample level | 18.3% (24/131) | Cancer-free plasma samples from TP53 carriers | Wong et al. 2024 (wong2024earlycancerdetection pages 8-9) | https://doi.org/10.1158/2159-8290.CD-23-0456 | 2024-10 |
| cfDNA false-positive rate, individual level | 30.1% (22/73) | Cancer-free TP53 carriers | Wong et al. 2024 (wong2024earlycancerdetection pages 8-9, wong2024earlycancerdetection pages 11-12) | https://doi.org/10.1158/2159-8290.CD-23-0456 | 2024-10 |
Table: This table compiles the main recent quantitative findings for Li-Fraumeni syndrome / heritable TP53-related cancer syndrome, including penetrance, prevalence, surveillance performance, and emerging liquid-biopsy metrics. It is useful as a quick reference for comparing risk estimates and screening yield across recent guidelines and studies.
| Domain | Recommendation item | Age group | Modality/interval | Notes | Source with URL and publication date |
|---|---|---|---|---|---|
| Testing | Modified Chompret criterion: proband with an LFS core tumor before age 46 years and at least one first- or second-degree relative with an LFS core tumor before age 56 years or with multiple tumors | Any | Germline TP53 testing indicated | Core tumors include breast cancer, soft-tissue sarcoma, osteosarcoma, CNS tumor, adrenocortical carcinoma; family history alone may miss de novo cases (sanchezheras2023seomclinicalguideline pages 2-4, frebourg2020guidelinesforthe pages 1-2) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Testing | Modified Chompret criterion: multiple primary tumors, two of which belong to the LFS core spectrum, with the first before age 46 years | Any | Germline TP53 testing indicated | Applies even without strong family history; supports broadened hTP53rc concept (sanchezheras2023seomclinicalguideline pages 2-4, sanchezheras2023seomclinicalguideline pages 1-2) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05 |
| Testing | Modified Chompret criterion: rare tumors strongly associated with TP53 (e.g., adrenocortical carcinoma, choroid plexus carcinoma, anaplastic embryonal rhabdomyosarcoma) regardless of family history | Pediatric/any | Germline TP53 testing indicated | SEOM and ERN recommend testing for specific childhood tumors; ERN also highlights hypodiploid ALL, SHH medulloblastoma, jaw osteosarcoma (sanchezheras2023seomclinicalguideline pages 2-4, frebourg2020guidelinesforthe pages 4-5) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Testing | Modified Chompret criterion: very early-onset breast cancer | Adults (women) | Germline TP53 testing for breast cancer diagnosed before age 31 years | Especially important because TP53 carriers may benefit from radiation-sparing management (sanchezheras2023seomclinicalguideline pages 2-4, frebourg2020guidelinesforthe pages 1-2) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Testing | Second primary malignancy arising in a prior radiotherapy field after a first core TP53 tumor before age 46 years | Any | Germline TP53 testing should be considered | Reflects concern that radiotherapy contributes to subsequent primary tumors in TP53 carriers (sanchezheras2023seomclinicalguideline pages 2-4, frebourg2020guidelinesforthe pages 1-2) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Testing | Presymptomatic/cascade testing for relatives of a known carrier | Adults first-degree relatives; selected children | Offer predictive testing; in children, test from birth when variant is associated with childhood cancer risk | Childhood testing is not systematic for clearly low-childhood-risk variants; decisions may be case-by-case (sanchezheras2023seomclinicalguideline pages 2-4, frebourg2020guidelinesforthe pages 4-5) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Testing | Variant allele fraction (VAF) interpretation in blood | Any | If VAF ~40–50%, constitutional/germline more likely; if VAF 10–40%, confirm in non-lymphoid tissue | Helps distinguish germline/constitutional mosaicism from clonal hematopoiesis or circulating tumor DNA (sanchezheras2023seomclinicalguideline pages 2-4) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05 |
| Testing | Timing of TP53 testing relative to cancer therapy | Any newly diagnosed cancer patient with suggestive phenotype | Test before treatment initiation when possible | Goal is to avoid radiotherapy and conventional genotoxic chemotherapy when feasible (frebourg2020guidelinesforthe pages 1-2, frebourg2020guidelinesforthe pages 3-4) | ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Surveillance | Start surveillance once carrier status is known and continue lifelong | Any confirmed carrier | Begin promptly; lifelong program | Applies to germline and constitutional mosaic TP53 pathogenic/likely pathogenic variants; some classic LFS families without identified TP53 variant may also undergo surveillance (sanchezheras2023seomclinicalguideline pages 4-6) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05 |
| Surveillance | Comprehensive physical examination | Children (birth–18 y) | Every 4–6 months | Typically coordinated by pediatric oncology/genetics team (sanchezheras2023seomclinicalguideline pages 4-6) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05 |
| Surveillance | Abdominal/pelvic ultrasound for ACC surveillance | Children (birth–18 y) | Every 3–6 months | ERN also recommends abdominal ultrasound every 6 months or 3–4 months depending on protocol; radiation-free modality preferred (sanchezheras2023seomclinicalguideline pages 4-6, frebourg2020guidelinesforthe pages 4-5, frebourg2020guidelinesforthe pages 3-4) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Surveillance | Endocrine/ACC laboratory surveillance | Children | Steroid hormone tests every 3–6 months when indicated; urine steroid monitoring probably every 6 months in ERN | Used because childhood ACC risk is clinically important; exact local protocol may vary (sanchezheras2023seomclinicalguideline pages 2-4, sanchezheras2023seomclinicalguideline pages 4-6, frebourg2020guidelinesforthe pages 4-5) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Surveillance | Brain MRI | Children | Annually from first year of life | First MRI with gadolinium; subsequent annual MRIs preferably without contrast; ERN suggests alternating with WBMRI so brain is imaged every 6 months in children (sanchezheras2023seomclinicalguideline pages 4-6, frebourg2020guidelinesforthe pages 4-5, frebourg2020guidelinesforthe pages 3-4) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Surveillance | Whole-body MRI (WBMRI) | Children | Annually | No ionizing radiation; usually performed without gadolinium in SEOM protocol; sedation may be needed in young children (sanchezheras2023seomclinicalguideline pages 4-6, kumamoto2021medicalguidelinesfor pages 1-2) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; LFS medical guideline 2021, https://doi.org/10.1007/s10147-021-02011-w, published 2021-10 |
| Surveillance | Complete blood count (CBC) | Children | Annually | Especially considered after leukemogenic therapy; no proven presymptomatic hematologic malignancy screening beyond this (sanchezheras2023seomclinicalguideline pages 2-4, sanchezheras2023seomclinicalguideline pages 4-6) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05 |
| Surveillance | Comprehensive physical examination | Adults | Every 6 months | Ideally coordinated by clinicians experienced in cancer genetics (sanchezheras2023seomclinicalguideline pages 4-6) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05 |
| Surveillance | Brain MRI | Adults | Annually until age 50 years | First MRI with gadolinium, then annual non-contrast MRI when possible (frebourg2020guidelinesforthe pages 1-2, sanchezheras2023seomclinicalguideline pages 4-6) | ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05; SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05 |
| Surveillance | Whole-body MRI (WBMRI) | Adults | Annually | Central element of surveillance; avoids ionizing radiation; baseline detection about 7% in guideline summaries (sanchezheras2023seomclinicalguideline pages 4-6, frebourg2020guidelinesforthe pages 3-4) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Surveillance | Clinical breast exam | Adult women | Every 6 months from age 20 years | Breast screening should minimize radiation exposure (sanchezheras2023seomclinicalguideline pages 4-6) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05 |
| Surveillance | Breast MRI | Adult women | Annually from age 20 to 75 years (SEOM); ERN 20–65 years | SEOM recommends alternating annual breast MRI with WBMRI at 6-month intervals; mammography generally avoided because of radiation sensitivity concerns (sanchezheras2023seomclinicalguideline pages 4-6, frebourg2020guidelinesforthe pages 1-2) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Surveillance | Risk-reducing bilateral mastectomy discussion | Adult women | Individualized counseling | Mentioned as an option to reduce breast cancer risk and future need for radiotherapy (sanchezheras2023seomclinicalguideline pages 4-6, kumamoto2021medicalguidelinesfor pages 1-2) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; LFS medical guideline 2021, https://doi.org/10.1007/s10147-021-02011-w, published 2021-10 |
| Surveillance | Colonoscopy | Adults | Every 5 years from age 18 if indicated | Usually reserved for those with prior abdominal radiotherapy or relevant family history (sanchezheras2023seomclinicalguideline pages 4-6, frebourg2020guidelinesforthe pages 4-5) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05; ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05 |
| Surveillance | Complete blood count (CBC) | Adults | Annually | Especially after leukemogenic treatment exposure; evidence for routine hematologic cancer screening remains limited (sanchezheras2023seomclinicalguideline pages 2-4, sanchezheras2023seomclinicalguideline pages 4-6) | SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05 |
| Surveillance | Radiation avoidance principle | All carriers | Prefer MRI/ultrasound-based surveillance; minimize mammography, CT, and radiotherapy when alternatives exist | Important because TP53 carriers are at increased risk of treatment-related subsequent primary tumors (frebourg2020guidelinesforthe pages 1-2, sanchezheras2023seomclinicalguideline pages 4-6, frebourg2020guidelinesforthe pages 3-4) | ERN GENTURIS guideline 2020, https://doi.org/10.1038/s41431-020-0638-4, published 2020-05; SEOM guideline 2023, https://doi.org/10.1007/s12094-023-03202-9, published 2023-05 |
Table: This table summarizes when to test for TP53 under modified Chompret and related criteria, and the main surveillance schedule for children and adults with heritable TP53-related cancer syndrome. It is useful as a guideline-oriented reference for diagnosis, cascade testing, and radiation-sparing surveillance planning.
A per-study summary table of whole-body MRI studies and detection rates from the 2024 systematic review/meta-analysis is available for visual corroboration. (temperley2024wholebodymriscreening media bbec6272)
References
(giovino2024newparadigmsin pages 2-4): Camilla Giovino, Vallijah Subasri, Frank Telfer, and David Malkin. New paradigms in the clinical management of li-fraumeni syndrome. Cold Spring Harbor perspectives in medicine, 14:a041584, May 2024. URL: https://doi.org/10.1101/cshperspect.a041584, doi:10.1101/cshperspect.a041584. This article has 11 citations and is from a peer-reviewed journal.
(sanchezheras2023seomclinicalguideline pages 1-2): Ana Beatriz Sánchez-Heras, Teresa Ramon y Cajal, Marta Pineda, Elena Aguirre, Begoña Graña, Isabel Chirivella, Judit Balmaña, and Joan Brunet. Seom clinical guideline on heritable tp53-related cancer syndrome (2022). Clinical & Translational Oncology, 25:2627-2633, May 2023. URL: https://doi.org/10.1007/s12094-023-03202-9, doi:10.1007/s12094-023-03202-9. This article has 13 citations and is from a peer-reviewed journal.
(frebourg2020guidelinesforthe pages 1-2): T. Frébourg, Svetlana Bajalica Lagercrantz, Carla Oliveira, R. Mágenheim, D. Evans, Nicoline Marjolijn Marleen Rianne Rolf Gareth Emma Marc Eam Hoogerbrugge Ligtenberg Kets Oostenbrink Sijmons E, N. Hoogerbrugge, M. Ligtenberg, M. Kets, R. Oostenbrink, R. Sijmons, G. Evans, E. Woodward, M. Tischkowitz, E. Maher, R. Ferner, S. Aretz, I. Spier, V. Steinke-Lange, E. Holinski-Feder, E. Schröck, T. Frébourg, C. Houdayer, C. Colas, P. Wolkenstein, V. Bours, E. Legius, B. Poppe, K. Claes, R. de Putter, I. Guillermo, G. Capellá, J. B. Vidal, C. Lázaro, J. Balmaña, H. S. Hernández, Carla Oliveira, M. Teixeira, S. Bajalica-Lagercrantz, E. Tham, J. Lubiński, K. Ertmańska, B. Melegh, M. Krajc, A. Blatnik, S. Peltonen, and M. Hietala. Guidelines for the li–fraumeni and heritable tp53-related cancer syndromes. European Journal of Human Genetics, 28:1379-1386, May 2020. URL: https://doi.org/10.1038/s41431-020-0638-4, doi:10.1038/s41431-020-0638-4. This article has 372 citations and is from a domain leading peer-reviewed journal.
(hosseini2024currentinsightsand pages 1-4): Mohammad-Salar Hosseini. Current insights and future directions of li-fraumeni syndrome. Discover Oncology, Oct 2024. URL: https://doi.org/10.1007/s12672-024-01435-w, doi:10.1007/s12672-024-01435-w. This article has 21 citations.
(fortuno2024cancerrisksassociated pages 1-2): Cristina Fortuno, Bing-Jian Feng, Courtney Carroll, Giovanni Innella, Wendy Kohlmann, Conxi Lázaro, Joan Brunet, Lidia Feliubadaló, Silvia Iglesias, Mireia Menéndez, Alex Teulé, Mandy L. Ballinger, David M. Thomas, Ainsley Campbell, Mike Field, Marion Harris, Judy Kirk, Nicholas Pachter, Nicola Poplawski, Rachel Susman, Kathy Tucker, Mathew Wallis, Rachel Williams, Elisa Cops, David Goldgar, Paul A. James, Amanda B. Spurdle, David Amor, Lesley Andrews, Yoland Antill, Rosemary Balleine, Jonathan Beesley, Ian Bennett, Michael Bogwitz, Simon Bodek, Leon Botes, Meagan Brennan, Melissa Brown, Michael Buckley, Jo Burke, Phyllis Butow, Liz Caldon, Ian Campbell, Michelle Cao, Anannya Chakrabarti, Deepa Chauhan, Manisha Chauhan, Georgia Chenevix-Trench, Alice Christian, Paul Cohen, Alison Colley, Ashley Crook, James Cui, Eliza Courtney, Margaret Cummings, Sarah-Jane Dawson, Anna deFazio, Martin Delatycki, Rebecca Dickson, Joanne Dixon, Ted Edkins, Stacey Edwards, Gelareh Farshid, Andrew Fellows, Georgina Fenton, Michael Field, James Flanagan, Peter Fong, Laura Forrest, Stephen Fox, Juliet French, Michael Friedlander, Clara Gaff, Mike Gattas, Peter George, Sian Greening, Marion Harris, Stewart Hart, Nick Hayward, John Hopper, Cass Hoskins, Clare Hunt, Paul James, Mark Jenkins, Alexa Kidd, Judy Kirk, Jessica Koehler, James Kollias, Sunil Lakhani, Mitchell Lawrence, Jason Lee, Shuai Li, Geoff Lindeman, Jocelyn Lippey, Lara Lipton, Liz Lobb, Sherene Loi, Graham Mann, Deborah Marsh, Sue Anne McLachlan, Bettina Meiser, Roger Milne, Sophie Nightingale, Shona O'Connell, Sarah O'Sullivan, David Gallego Ortega, Nick Pachter, Jia-Min Pang, Gargi Pathak, Briony Patterson, Amy Pearn, Kelly Phillips, Ellen Pieper, Susan Ramus, Edwina Rickard, Bridget Robinson, Mona Saleh, Anita Skandarajah, Elizabeth Salisbury, Christobel Saunders, Jodi Saunus, Peter Savas, Rodney Scott, Clare Scott, Adrienne Sexton, Joanne Shaw, Andrew Shelling, Shweta Srinivasa, Peter Simpson, Melissa Southey, Amanda Spurdle, Jessica Taylor, Renea Taylor, Heather Thorne, Alison Trainer, Kathy Tucker, Jane Visvader, Logan Walker, Rachael Williams, Ingrid Winship, Mary Ann Young, and Milita Zaheed. Cancer risks associated with tp53 pathogenic variants: maximum likelihood analysis of extended pedigrees for diagnosis of first cancers beyond the li-fraumeni syndrome spectrum. JCO Precision Oncology, Feb 2024. URL: https://doi.org/10.1200/po.23.00453, doi:10.1200/po.23.00453. This article has 30 citations and is from a peer-reviewed journal.
(temperley2024wholebodymriscreening pages 11-13): Hugo C. Temperley, Niall J. O’Sullivan, Benjamin M. Mac Curtain, Wanyang Qian, Tatiana S. Temperley, Alannah Murray, Alison Corr, Ian Brennan, David Gallagher, James F. Meaney, and Michael E. Kelly. Whole-body mri screening for carriers of germline tp53 mutations—a systematic review and meta-analysis. Journal of Clinical Medicine, 13:1223, Feb 2024. URL: https://doi.org/10.3390/jcm13051223, doi:10.3390/jcm13051223. This article has 5 citations.
(wong2024earlycancerdetection pages 1-3): Derek Wong, Ping Luo, Leslie E. Oldfield, Haifan Gong, Ledia Brunga, Ron Rabinowicz, Vallijah Subasri, Clarissa Chan, Tiana Downs, Kirsten M. Farncombe, Beatrice Luu, Maia Norman, Julia A. Sobotka, Precious Uju, Jenna Eagles, Stephanie Pedersen, Johanna Wellum, Arnavaz Danesh, Stephenie D. Prokopec, Eric Y. Stutheit-Zhao, Nadia Znassi, Lawrence E. Heisler, Richard Jovelin, Bernard Lam, Beatriz E. Lujan Toro, Kayla Marsh, Yogi Sundaravadanam, Dax Torti, Carina Man, Anna Goldenberg, Wei Xu, Patrick Veit-Haibach, Andrea S. Doria, David Malkin, Raymond H. Kim, and Trevor J. Pugh. Early cancer detection in li–fraumeni syndrome with cell-free dna. Cancer Discovery, 14:104-119, Oct 2024. URL: https://doi.org/10.1158/2159-8290.cd-23-0456, doi:10.1158/2159-8290.cd-23-0456. This article has 57 citations and is from a highest quality peer-reviewed journal.
(andrade2024genomefirstapproachof pages 2-3): Kelvin C. de Andrade, Natasha T. Strande, Jung Kim, Jeremy S. Haley, Jessica N. Hatton, Megan N. Frone, Payal P. Khincha, Gretchen M. Thone, Uyenlinh L. Mirshahi, Cynthia Schneider, Heena Desai, James T. Dove, Diane T. Smelser, Arnold J. Levine, Kara N. Maxwell, Douglas R. Stewart, David J. Carey, and Sharon A. Savage. Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline tp53 variants. Human Genetics and Genomics Advances, 5:100242, Jan 2024. URL: https://doi.org/10.1016/j.xhgg.2023.100242, doi:10.1016/j.xhgg.2023.100242. This article has 28 citations and is from a peer-reviewed journal.
(dixonzegeye2024cancerprecisionpreventiontrial pages 1-2): Miriam Dixon-Zegeye, Rachel Shaw, Linda Collins, Kendra Perez-Smith, Alexander Ooms, Maggie Qiao, Pan Pantziarka, Louise Izatt, Marc Tischkowitz, Rachel E. Harrison, Angela George, Emma R. Woodward, Simon Lord, Lara Hawkes, D. Gareth Evans, James Franklin, Helen Hanson, and Sarah P. Blagden. Cancer precision-prevention trial of metformin in adults with li fraumeni syndrome (mili) undergoing yearly mri surveillance: a randomised controlled trial protocol. Trials, Feb 2024. URL: https://doi.org/10.1186/s13063-024-07929-w, doi:10.1186/s13063-024-07929-w. This article has 19 citations and is from a peer-reviewed journal.
(light2023germlinetp53mutations pages 6-7): Nicholas Light, Mehdi Layeghifard, Ayush Attery, Vallijah Subasri, Matthew Zatzman, Nathaniel D Anderson, Rupal Hatkar, Sasha Blay, David Chen, Ana Novokmet, Fabio Fuligni, James Tran, Richard De Borja, Himanshi Agarwal, Larissa Waldman, Lisa M Abegglen, Daniel Albertson, Jonathan L Finlay, Jordan R Hansford, Sam Behjati, Anita Villani, Moritz Gerstung, Ludmil B Alexandrov, Gino R Somers, Joshua D Schiffman, Varda Rotter, David Malkin, and Adam Shlien. Germline tp53 mutations undergo copy number gain years prior to tumor diagnosis. JournalArticle, Feb 2023. URL: https://doi.org/10.17863/cam.93707, doi:10.17863/cam.93707. This article has 42 citations.
(gargallo2020li–fraumenisyndromeheterogeneity pages 2-4): P. Gargallo, Y. Yáñez, V. Segura, A. Juan, B. Torres, J. Balaguer, S. Oltra, V. Castel, and A. Cañete. Li–fraumeni syndrome heterogeneity. Clinical and Translational Oncology, 22:978-988, Nov 2020. URL: https://doi.org/10.1007/s12094-019-02236-2, doi:10.1007/s12094-019-02236-2. This article has 51 citations and is from a peer-reviewed journal.
(gargallo2020li–fraumenisyndromeheterogeneity pages 7-8): P. Gargallo, Y. Yáñez, V. Segura, A. Juan, B. Torres, J. Balaguer, S. Oltra, V. Castel, and A. Cañete. Li–fraumeni syndrome heterogeneity. Clinical and Translational Oncology, 22:978-988, Nov 2020. URL: https://doi.org/10.1007/s12094-019-02236-2, doi:10.1007/s12094-019-02236-2. This article has 51 citations and is from a peer-reviewed journal.
(frebourg2020guidelinesforthe pages 4-5): T. Frébourg, Svetlana Bajalica Lagercrantz, Carla Oliveira, R. Mágenheim, D. Evans, Nicoline Marjolijn Marleen Rianne Rolf Gareth Emma Marc Eam Hoogerbrugge Ligtenberg Kets Oostenbrink Sijmons E, N. Hoogerbrugge, M. Ligtenberg, M. Kets, R. Oostenbrink, R. Sijmons, G. Evans, E. Woodward, M. Tischkowitz, E. Maher, R. Ferner, S. Aretz, I. Spier, V. Steinke-Lange, E. Holinski-Feder, E. Schröck, T. Frébourg, C. Houdayer, C. Colas, P. Wolkenstein, V. Bours, E. Legius, B. Poppe, K. Claes, R. de Putter, I. Guillermo, G. Capellá, J. B. Vidal, C. Lázaro, J. Balmaña, H. S. Hernández, Carla Oliveira, M. Teixeira, S. Bajalica-Lagercrantz, E. Tham, J. Lubiński, K. Ertmańska, B. Melegh, M. Krajc, A. Blatnik, S. Peltonen, and M. Hietala. Guidelines for the li–fraumeni and heritable tp53-related cancer syndromes. European Journal of Human Genetics, 28:1379-1386, May 2020. URL: https://doi.org/10.1038/s41431-020-0638-4, doi:10.1038/s41431-020-0638-4. This article has 372 citations and is from a domain leading peer-reviewed journal.
(sanchezheras2023seomclinicalguideline pages 2-4): Ana Beatriz Sánchez-Heras, Teresa Ramon y Cajal, Marta Pineda, Elena Aguirre, Begoña Graña, Isabel Chirivella, Judit Balmaña, and Joan Brunet. Seom clinical guideline on heritable tp53-related cancer syndrome (2022). Clinical & Translational Oncology, 25:2627-2633, May 2023. URL: https://doi.org/10.1007/s12094-023-03202-9, doi:10.1007/s12094-023-03202-9. This article has 13 citations and is from a peer-reviewed journal.
(kumamoto2021medicalguidelinesfor pages 1-2): Tadashi Kumamoto, Fumito Yamazaki, Yoshiko Nakano, Chieko Tamura, Shimon Tashiro, Hiroyoshi Hattori, Akira Nakagawara, and Yukiko Tsunematsu. Medical guidelines for li–fraumeni syndrome 2019, version 1.1. International Journal of Clinical Oncology, 26:2161-2178, Oct 2021. URL: https://doi.org/10.1007/s10147-021-02011-w, doi:10.1007/s10147-021-02011-w. This article has 87 citations and is from a peer-reviewed journal.
(andrade2024genomefirstapproachof pages 3-4): Kelvin C. de Andrade, Natasha T. Strande, Jung Kim, Jeremy S. Haley, Jessica N. Hatton, Megan N. Frone, Payal P. Khincha, Gretchen M. Thone, Uyenlinh L. Mirshahi, Cynthia Schneider, Heena Desai, James T. Dove, Diane T. Smelser, Arnold J. Levine, Kara N. Maxwell, Douglas R. Stewart, David J. Carey, and Sharon A. Savage. Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline tp53 variants. Human Genetics and Genomics Advances, 5:100242, Jan 2024. URL: https://doi.org/10.1016/j.xhgg.2023.100242, doi:10.1016/j.xhgg.2023.100242. This article has 28 citations and is from a peer-reviewed journal.
(sanchezheras2023seomclinicalguideline pages 4-6): Ana Beatriz Sánchez-Heras, Teresa Ramon y Cajal, Marta Pineda, Elena Aguirre, Begoña Graña, Isabel Chirivella, Judit Balmaña, and Joan Brunet. Seom clinical guideline on heritable tp53-related cancer syndrome (2022). Clinical & Translational Oncology, 25:2627-2633, May 2023. URL: https://doi.org/10.1007/s12094-023-03202-9, doi:10.1007/s12094-023-03202-9. This article has 13 citations and is from a peer-reviewed journal.
(vanikova2024functionalanalysisof pages 67-70): L Vaníková. Functional analysis of selected variants of uncertain significance in cancer predisposing genes. Unknown journal, 2024.
(light2023germlinetp53mutations pages 1-2): Nicholas Light, Mehdi Layeghifard, Ayush Attery, Vallijah Subasri, Matthew Zatzman, Nathaniel D Anderson, Rupal Hatkar, Sasha Blay, David Chen, Ana Novokmet, Fabio Fuligni, James Tran, Richard De Borja, Himanshi Agarwal, Larissa Waldman, Lisa M Abegglen, Daniel Albertson, Jonathan L Finlay, Jordan R Hansford, Sam Behjati, Anita Villani, Moritz Gerstung, Ludmil B Alexandrov, Gino R Somers, Joshua D Schiffman, Varda Rotter, David Malkin, and Adam Shlien. Germline tp53 mutations undergo copy number gain years prior to tumor diagnosis. JournalArticle, Feb 2023. URL: https://doi.org/10.17863/cam.93707, doi:10.17863/cam.93707. This article has 42 citations.
(andrade2024genomefirstapproachof pages 6-7): Kelvin C. de Andrade, Natasha T. Strande, Jung Kim, Jeremy S. Haley, Jessica N. Hatton, Megan N. Frone, Payal P. Khincha, Gretchen M. Thone, Uyenlinh L. Mirshahi, Cynthia Schneider, Heena Desai, James T. Dove, Diane T. Smelser, Arnold J. Levine, Kara N. Maxwell, Douglas R. Stewart, David J. Carey, and Sharon A. Savage. Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline tp53 variants. Human Genetics and Genomics Advances, 5:100242, Jan 2024. URL: https://doi.org/10.1016/j.xhgg.2023.100242, doi:10.1016/j.xhgg.2023.100242. This article has 28 citations and is from a peer-reviewed journal.
(temperley2024wholebodymriscreening pages 9-11): Hugo C. Temperley, Niall J. O’Sullivan, Benjamin M. Mac Curtain, Wanyang Qian, Tatiana S. Temperley, Alannah Murray, Alison Corr, Ian Brennan, David Gallagher, James F. Meaney, and Michael E. Kelly. Whole-body mri screening for carriers of germline tp53 mutations—a systematic review and meta-analysis. Journal of Clinical Medicine, 13:1223, Feb 2024. URL: https://doi.org/10.3390/jcm13051223, doi:10.3390/jcm13051223. This article has 5 citations.
(wong2024earlycancerdetection pages 9-11): Derek Wong, Ping Luo, Leslie E. Oldfield, Haifan Gong, Ledia Brunga, Ron Rabinowicz, Vallijah Subasri, Clarissa Chan, Tiana Downs, Kirsten M. Farncombe, Beatrice Luu, Maia Norman, Julia A. Sobotka, Precious Uju, Jenna Eagles, Stephanie Pedersen, Johanna Wellum, Arnavaz Danesh, Stephenie D. Prokopec, Eric Y. Stutheit-Zhao, Nadia Znassi, Lawrence E. Heisler, Richard Jovelin, Bernard Lam, Beatriz E. Lujan Toro, Kayla Marsh, Yogi Sundaravadanam, Dax Torti, Carina Man, Anna Goldenberg, Wei Xu, Patrick Veit-Haibach, Andrea S. Doria, David Malkin, Raymond H. Kim, and Trevor J. Pugh. Early cancer detection in li–fraumeni syndrome with cell-free dna. Cancer Discovery, 14:104-119, Oct 2024. URL: https://doi.org/10.1158/2159-8290.cd-23-0456, doi:10.1158/2159-8290.cd-23-0456. This article has 57 citations and is from a highest quality peer-reviewed journal.
(wong2024earlycancerdetection pages 8-9): Derek Wong, Ping Luo, Leslie E. Oldfield, Haifan Gong, Ledia Brunga, Ron Rabinowicz, Vallijah Subasri, Clarissa Chan, Tiana Downs, Kirsten M. Farncombe, Beatrice Luu, Maia Norman, Julia A. Sobotka, Precious Uju, Jenna Eagles, Stephanie Pedersen, Johanna Wellum, Arnavaz Danesh, Stephenie D. Prokopec, Eric Y. Stutheit-Zhao, Nadia Znassi, Lawrence E. Heisler, Richard Jovelin, Bernard Lam, Beatriz E. Lujan Toro, Kayla Marsh, Yogi Sundaravadanam, Dax Torti, Carina Man, Anna Goldenberg, Wei Xu, Patrick Veit-Haibach, Andrea S. Doria, David Malkin, Raymond H. Kim, and Trevor J. Pugh. Early cancer detection in li–fraumeni syndrome with cell-free dna. Cancer Discovery, 14:104-119, Oct 2024. URL: https://doi.org/10.1158/2159-8290.cd-23-0456, doi:10.1158/2159-8290.cd-23-0456. This article has 57 citations and is from a highest quality peer-reviewed journal.
(NCT01737255 chunk 1): Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome. Institute of Cancer Research, United Kingdom. 2012. ClinicalTrials.gov Identifier: NCT01737255
(NCT02950987 chunk 1): Allison O'Neill, MD. Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes. Dana-Farber Cancer Institute. 2012. ClinicalTrials.gov Identifier: NCT02950987
(NCT03176836 chunk 1): Andrea Doria. Li-Fraumeni Syndrome Imaging Study. The Hospital for Sick Children. 2016. ClinicalTrials.gov Identifier: NCT03176836
(NCT04367246 chunk 1): Kara Maxwell. Li-Fraumeni Syndrome/TP53 Biobank. Abramson Cancer Center at Penn Medicine. 2019. ClinicalTrials.gov Identifier: NCT04367246
(levine2021spontaneousandinherited pages 1-2): Arnold J. Levine. Spontaneous and inherited tp53 genetic alterations. Oncogene, 40:5975-5983, Aug 2021. URL: https://doi.org/10.1038/s41388-021-01991-3, doi:10.1038/s41388-021-01991-3. This article has 69 citations and is from a domain leading peer-reviewed journal.
(wong2024earlycancerdetection pages 11-12): Derek Wong, Ping Luo, Leslie E. Oldfield, Haifan Gong, Ledia Brunga, Ron Rabinowicz, Vallijah Subasri, Clarissa Chan, Tiana Downs, Kirsten M. Farncombe, Beatrice Luu, Maia Norman, Julia A. Sobotka, Precious Uju, Jenna Eagles, Stephanie Pedersen, Johanna Wellum, Arnavaz Danesh, Stephenie D. Prokopec, Eric Y. Stutheit-Zhao, Nadia Znassi, Lawrence E. Heisler, Richard Jovelin, Bernard Lam, Beatriz E. Lujan Toro, Kayla Marsh, Yogi Sundaravadanam, Dax Torti, Carina Man, Anna Goldenberg, Wei Xu, Patrick Veit-Haibach, Andrea S. Doria, David Malkin, Raymond H. Kim, and Trevor J. Pugh. Early cancer detection in li–fraumeni syndrome with cell-free dna. Cancer Discovery, 14:104-119, Oct 2024. URL: https://doi.org/10.1158/2159-8290.cd-23-0456, doi:10.1158/2159-8290.cd-23-0456. This article has 57 citations and is from a highest quality peer-reviewed journal.
(frebourg2020guidelinesforthe pages 3-4): T. Frébourg, Svetlana Bajalica Lagercrantz, Carla Oliveira, R. Mágenheim, D. Evans, Nicoline Marjolijn Marleen Rianne Rolf Gareth Emma Marc Eam Hoogerbrugge Ligtenberg Kets Oostenbrink Sijmons E, N. Hoogerbrugge, M. Ligtenberg, M. Kets, R. Oostenbrink, R. Sijmons, G. Evans, E. Woodward, M. Tischkowitz, E. Maher, R. Ferner, S. Aretz, I. Spier, V. Steinke-Lange, E. Holinski-Feder, E. Schröck, T. Frébourg, C. Houdayer, C. Colas, P. Wolkenstein, V. Bours, E. Legius, B. Poppe, K. Claes, R. de Putter, I. Guillermo, G. Capellá, J. B. Vidal, C. Lázaro, J. Balmaña, H. S. Hernández, Carla Oliveira, M. Teixeira, S. Bajalica-Lagercrantz, E. Tham, J. Lubiński, K. Ertmańska, B. Melegh, M. Krajc, A. Blatnik, S. Peltonen, and M. Hietala. Guidelines for the li–fraumeni and heritable tp53-related cancer syndromes. European Journal of Human Genetics, 28:1379-1386, May 2020. URL: https://doi.org/10.1038/s41431-020-0638-4, doi:10.1038/s41431-020-0638-4. This article has 372 citations and is from a domain leading peer-reviewed journal.
(temperley2024wholebodymriscreening media bbec6272): Hugo C. Temperley, Niall J. O’Sullivan, Benjamin M. Mac Curtain, Wanyang Qian, Tatiana S. Temperley, Alannah Murray, Alison Corr, Ian Brennan, David Gallagher, James F. Meaney, and Michael E. Kelly. Whole-body mri screening for carriers of germline tp53 mutations—a systematic review and meta-analysis. Journal of Clinical Medicine, 13:1223, Feb 2024. URL: https://doi.org/10.3390/jcm13051223, doi:10.3390/jcm13051223. This article has 5 citations.